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PREFACE 
 
The DREAM Program (Disease Relief through Excellent and Advanced Means) was formed 
and run by the Community of Sant’Egidio, a catholic international organization born in Italy in 
1968. Initially was an HIV and nutrition care NGO, and now is a global health care institution 
for communicable and non-communicable diseases (DREAM 2.0) with programs on 
tuberculosis, cervical cancer, hypertension, diabetes, and others. Designed for quality and 
based on partnerships, is a public health program as well as applied research. All our 
services are free of charge. 
DREAM started in Mozambique in 2002 and is now in 11 other countries with 47 health 
centers, 24 molecular biology laboratories and 300,000 patients assisted from 2002, 130,000 
patients on HAART of whom 15,000 children. Millions of peoples reached by the program and 
50,000  children were born healthy in the PMTCT program  
The laboratory monitoring is part of an holistic approach that DREAM uses in routine patient 
care. The laboratories perform Blood count, Biochemistry, CD4 count, HIV-1 viral load, Infant 
virological testing and, in Malawi and Mozambique, HIV genotyping, initially with Trugene 
platform (Siemens Health Care Diagnostics), now with a validated in-house method. 
The promotion of laboratory medicine in management of HIV positive population in Malawi is 
one of the major contributions that DREAM Program has impacted to the Country. When 
DREAM rolled out its program in 2005, Malawi did not have any molecular biology laboratory 
for routine patient care, but owing to the training, advocacy and setting up of model 
infrastructures by DREAM, the Country has registered significant developments and now 10 
molecular laboratories are spread across the Country for viral load and infant virological 
testing. 
The Malawi ART guidelines recommends an HIV genotyping test for all patients failing second 
line regimens before switching them to third line regimens. There is also need for genotyping 
services for surveillance studies. DREAM Malawi program has the only genotyping facility in 
the Country at its Blantyre laboratory since 2008, which is also available for all public 
structures. DREAM has a leading role to share expertise in HIV drug resistance services in 
Malawi even now, that the Country has established a genotyping lab at National HIV 
Laboratory in Lilongwe. 
 
SUMMARY 
 
The aim of the PhD study was to describe retrospectively the prevalence of transmitted HIV-1 
resistance mutations in a cohort of naïve patients starting treatment at DREAM program 
health centers in Malawi. In Africa naïve resistance mutations rate is unknown or 
underestimated.  
In Malawi in 2014, 1.8 million people have turned to the services of HTC (HIV testing and 
counseling) (Malawi National AIDS Commission). There are also important results on the 
treatment front: as many as 61% of adults with HIV are under anti-retroviral therapy (ART), 
67.6% of whom are effective virological suppression. Moreover, the estimate frequency of 
Transmitted HIV drug resistance (TDR) in the Country is based on a very limited number of 
specimen, and more studies were needed to support the national surveillance supplying 
programmatic information in designing education and prevention programs as well as 
supporting a wise use of antiretroviral drugs by clinicians and policy makers. 
Simultaneous to this study, analyzing the viral sequences, we tried to highlight some 
polymorphism patterns to study them and compare with other patterns related to other HIV-1 
subtypes (as B, present in Western Countries, when in Malawi the major subtype described is 
C ).  
Most of the activities were developed in Blantyre DREAM laboratory. An affordable laboratory 
method is needed in Low Limited Setting (LLS) as Malawi, to obtain the virus sequences, in 
order to allow national structures to produce data locally and to dramatically improve the 
number of performed tests. For this reason in the PhD meantime a homemade cost effective 
method able to detect HIV drug resistances was developed and successfully used.  
The study provides some important information in understanding the transmitted resistance 
rate in the Country Out of 109 samples from naïve patients, 40 (36,70%) presented at least 
one TDR-associated mutation, The observed frequency of nucleoside reverse transcriptase 
inhibitors (NRTIs) resistance mutations was: M184V (4,58%), K70R/E (3,67%),D67N (2,75%). 
The prevalence of resistance mutations to non-nucleoside reverse transcriptase inhibitor 
(NNRTI) was K103N/S (11,93%), G190A (6,42%), Y181C/V (3,67%), V106M (2,75%).  
The study showed that there is an increase in NNRTI resistance and that the activity of 
NNRTIs is compromised because of the high level of NNRTI resistance. 
However in developing African countries, the majority of first line ART regimens are 
nevirapine/efarinenz (NVP/EFV) based, but these drugs are responsible for selection of 
mutations to the entire class of NNRTI (K103N, Y181C and G190A). The study confirms the 
need to review the treatment protocols because the use of NNRTIs could be the cause in the 
increase of resistance. 
Given such levels of HIV Drug Resistance (HIVDR) prevalence, HIVDR testing and 
surveillance capacity in Malawi should be prioritized as scale-up and the adoption of the 
universal ART eligibility for people living with HIV (PLHIV). 
To highlight the polymorphism patterns, of the 216 codons subjected to nucleotide variations 
found through all the sequencing products, the most represented ones were selected to 
ensure greater statistical significance, reducing the number to 22 codon. 
Many of these polymorphisms were found to be present in very high percentages, making it 
part of the consensus sequence for the subtype C. 
The association of V60I with all three mutations of the NAM-1 pathway, the positive 
association of L228R and negative of S48T/Q with M41L and L210W are very significant. 
Very significant associations are found between the L228R and all 4 mutations of the NAM-2 
pathway, and the associations of V60I and I135T/M with two mutations each. The negative 
associations with S48T/Q and K173T are also very evident. The most significant associations 
are those with I135T / M (positive) and with V245Q (negative). The associations highlighted 
by a previous study on subtype B have been compared and the only concordances found 
concern the association of L228R with the mutations of the NAM-2 pathway and of T39A with 
the mutations for NRTI. 
All these findings underline how subtypes B and C are characterized by substantially different 
mutational profiles. 
These associations are even more significant considering that three polymorphisms were 
found with very high frequency (81.2% for T39E/D, 55.0% for Q174T and 71.3% for R211K) 
enough to be considered part of the consensus sequence of the subtype C, and resulting 
associated with NNRTI resistance mutations, one could suspect their role in making the 
subtype C naturally more likely to develop resistance to NNRTIs. 
 
 
 
SOMMARIO 
Lo scopo dello studio di dottorato è stato quello di descrivere retrospettivamente la 
prevalenza delle mutazioni di resistenza HIV-1 trasmesse in una coorte di pazienti naïve che 
iniziano il trattamento presso i centri sanitari del programma DREAM in Malawi.  
In Africa infatti il tasso di mutazioni di resistenza naïve è sconosciuto o sottostimato. 
Nel 2014, in Malawi, 1,8 milioni di persone si sono rivolte ai servizi di HTC (test HIV e 
counselling) (Malawi National AIDS Commission). Ci sono stati importanti risultati sul fronte 
del trattamento antiretrovirale (ART): ben il 61% degli adulti con HIV è in trattamento con 
ART, il 67,6% dei quali mostra una efficace soppressione virologica. Inoltre, la frequenza 
stimata della resistenza trasmessa ai farmaci contro l'HIV (TDR) nel Paese si basa su un 
numero molto limitato di campioni e sono necessari ulteriori studi per supportare il 
programma di sorveglianza nazionale, che fornisce informazioni alla progettazione di 
programmi di educazione e prevenzione e per sostenere un uso saggio dei farmaci 
antiretrovirali da parte di medici e responsabili politici. 
Contestualmente a questo studio, analizzando le sequenze virali, abbiamo provato a mettere 
in evidenza alcuni pattern di polimorfismi per studiarli e e confrontarli con pattern relativi ad 
altri sottotipi di HIV 1 (in particolare il B, maggiormente diffuso nei Paesi Occidentali, mentre 
in Malawi il sottotipo maggiore descritto è C).  
La maggior parte delle attività sono state sviluppate nel laboratorio DREAM a Blantyre. 
Per ottenere le sequenze di virus è stato necessario sviluppare un metodo di laboratorio a 
basso costo, per permettere a Paesi come il Malawi di ottenere le sequenze virali in modo 
sostenibile, al fine di consentire alle strutture nazionali di produrre dati localmente e di 
aumentare notevolmente il numero di test eseguiti. Per questo motivo nel dottorato di ricerca 
è stato sviluppato all'interno del laboratorio e utilizzato con successo un metodo 
economicamente efficace in grado di rilevare le resistenze ai farmaci dell'HIV. 
Lo studio fornisce alcune importanti informazioni sulla comprensione del tasso di resistenza 
trasmessa nel Paese. Su 109 campioni di pazienti naïve, 40 (36,70%) hanno presentato 
almeno una mutazione associata a TDR. La frequenza osservata delle mutazioni di 
resistenza agli  inibitori della trascrittasi inversa nucleosidica (NRTI) era per M184V (4,58%), 
K70R/E (3,67%),D67N (2,75%). La prevalenza di mutazioni di resistenza relativamente agli 
inibitori della trascrittasi inversa non nucleosidica (NNRTI) era K103N/S (11,93%), G190A 
(6,42%), Y181C/V (3,67%), V106M (2,75%).  
Lo studio ha mostrato che c'è un aumento della resistenza NNRTI e che l'attività degli NNRTI 
è compromessa a causa dell'alto livello di resistenza. 
In molti paesi africani in via di sviluppo, la maggior parte dei regimi ART di prima linea sono 
basati su neviralian/efavirenz (NVP / EFV), ma questi farmaci sono responsabili della 
selezione delle mutazioni dell'intera classe di NNRTI (K103N, Y181C e G190A). Lo studio 
conferma quindi la necessità di revisione dei protocolli di trattamento perché l'uso di NNRTI 
potrebbe essere la causa dell'aumento di resistenza. 
Dati tali livelli di prevalenza dell'HIV Drug Resistance (HIVDR), i test di resistenza e la 
capacità di sorveglianza epidemiologica in Malawi dovrebbero essere prioritari, viste le nuove 
politiche di accesso universale al trattamento. 
Per evidenziare i patterns di polimorfismo, sono stati selezionati i piu' rappresentativi tra i 216 
codoni che presentavano variazioni dei nucleotidi, per garantire una maggiore significatività 
statistica, riducendo il numero a 22 codoni. 
Molti di questi polimorfismi sono stati riscontrati in percentuali molto alte, rendendoli parte 
della sequenza di consenso per il sottotipo C. 
L'associazione di V60I con tutte e tre le mutazioni di NAM-1, l'associazione positiva di L228R 
e negativa di S48T/Q con M41L e L210W sono molto significative. 
Associazioni molto significative si trovano tra L228R e tutte le 4 mutazioni del pathway NAM-2 
e le associazioni di V60I  e I135T/M con due mutazioni ciascuna. Anche le associazioni 
negative con S48T/Q e K173T sono molto evidenti. Le associazioni più significative sono 
quelle con I135T/M (positiva) e con V245Q (negativa). 
Le associazioni evidenziate da uno studio precedente sul sottotipo B sono state confrontate e 
le uniche concordanze riscontrate riguardano l'associazione di L228R con le mutazioni del 
percorso NAM-2 e del T39A con le mutazioni per NRTI. 
Tutti questi dati sottolineano come i sottotipi B e C siano caratterizzati da profili mutazionali 
sostanzialmente diversi. 
Queste associazioni sono ancora più significative considerando che questi tre polimorfismi 
sono stati trovati con altissima frequenza (81,2% per T39E / D, 55,0% per Q174K e 71,3% 
per R211K) abbastanza da essere considerati parte della sequenza di consenso del sottotipo 
C, e risultando associati a mutazioni di resistenza, si potrebbe sospettare il loro ruolo nel 
rendere il sottotipo C naturalmente più probabile che sviluppi resistenza agli NNRTI. 
 
INTRODUCTION 
 
1.1 Characteristics of the human immunodeficiency virus (HIV) 
 
The human immunodeficiency virus (HIV), the etiologic agent of acquired immunodeficiency 
syndrome (AIDS), belongs to the Retroviridae family. 
Currently two HIV serotypes are known: HIV-1, which refers to genetically related viruses 
found predominantly in different regions of central and southern Africa, Asia, Europe and 
America (1) and HIV-2 which is a distinct virus prevalent in certain West African countries (2). 
Although both of these viruses cause AIDS, all individuals infected with HIV-2 have a long 
period of latency and low mortality. 
 
1.2 Classification of the human immunodeficiency virus 
 
Traditionally, the Retroviruses, which until the beginning of the 80s were known and studied 
for neoplastic diseases caused only in some species of animals, are classified into three sub-
families: Oncovirinae, Spumavirinae and Lentivirinae. 
Viruses originally isolated as transforming agents are grouped into oncoviruses. They cause 
sarcomas, leukemia, mammary tumors and, in some cases, a variable suppression of the 
immune system in different species of animals. 
Two human retroviruses, identified for the first time in 1980 by R.C. Gallo and his 
collaborators, are also part of this family: Human T Lymphoma viruses I and II (HTLV I-II) 
associated with T-cell lymphomas and neurological disorders. 
Spumaviruses owe their name to the ability to induce vacuolar lesions that give a foamy 
appearance to cells grown in vitro. 
Lentiviruses are associated with long-term diseases but without a direct relationship with the 
neoplasms. Before HIV-1 was isolated and characterized, Lentiviruses were known for 
diseases caused in some species of felines and ungulates. From the study of these viruses, 
much information has been received about the pathogenesis of AIDS. 
HIV-1 is classified as a member of the Lentivirus group based on its gene organization, 
similarity of nucleotide sequences and the type of pathology it entails, characterized by a long 
phase of clinical latency. Lentiviruses are viruses that induce chronic degenerative diseases 
in their hosts, preceded by a long incubation period and by a variable involvement of the 
immune system and the central nervous system. 
Another characteristic that finally distinguishes Lentiviruses is the complexity of the genome. 
Human-isolated Lentiviruses are grouped into two types named HIV-1 and HIV-2 based on 
serological and sequence properties (16,17). 
A classification based on the env gene sequences, described in the 1998 HIV Compendium 
(18), recognizes several HIV-1 subtypes or clades (19). 
Within each subtype, there is a high degree of variability. Although mutations appear to be the 
most responsible factor for viral variation, it has been postulated that recombination 
mechanisms may also occur in individuals infected with viruses of different HIV-1 (19) and 
HIV-2 clades (20). 
Some areas of the world mainly host a single subtype, while two or more subtypes may be 
prevalent in other populations (19). 
Molecular epidemiological studies indicate that the pattern of global distribution and variation 
is due to viral migration rather than viral mutation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Morphology and structure 
 
1.3.1 Structure of the virions 
 
Virions are the extracellular particles produced by cells infected with HIV-1. Figure 1 is a 
schematic representation of the virus and its components. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: HIV structure 
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Electron microscopy shows that the virion particles have a spherical shape with a diameter of 
110 nm and are formed by an external pericapside, the envelope, consisting of a double 
phospholipid layer on which virus-specific proteins anchor. In fact, the envelope contains 
about 72 triangular symmetry protuberances (21,22) each consisting of three or four 
heterodimers of the glycoprotein encoded by the env gene. Each heterodimer is composed of 
two subunits, one of which (gp120), which protrudes totally outwards, contains the domains 
that recognize and bind the CD4 receptor and the specific coreceptor for entry into the 
different target cells of the virus, while the other one (gp41), which is mostly inserted in the 
double phospholipidic layer, has a fusogenic  activity. 
The envelope also contains some cellular proteins, such as histocompatibility antigens 
(MHC), acquired during the budding process through the cell membrane. 
Associated with the internal face of the double phospholipidic layer, a matrix protein structure 
is observed, consisting of the p17 protein, which forms an internal thickening of the double 
phospholipid layer. 
Inside the viral particle is the nucleocapside or central core with a truncated cone structure. 
The nucleocapside crosses the entire diameter of the virion and the narrow end of the cone 
appears to be connected to the lipid double layer with a proteinaceous structure named CEL 
(core-envelope link) (23). The region between the nucleocapside and the envelope is called 
the paranucleoid region (24). The composition of CEL and the paranucleoid region must still 
be determined. 
The nucleocapside consists of two single-stranded viral RNA molecules encapsulated by 
proteins that derive from the precursor polypeptide synthesized by the gag gene. This 
precursor is cut from the viral protease into four protein products: p24, the main capsid 
protein, whose function is to package the viral genome in virions; the p17 or matrix protein, 
which as mentioned is located between the nucleocapside and the virion envelope, the p9, 
protein of the nucleocapside that binds tightly to the genome and finally the p7 whose location 
is not yet clear (25). These proteins are assembled according to an icosahedral type cubic 
symmetry. 
Inside the core, in addition to the nominal RNA, there are RNA transfer (tRNA) molecules and 
some viral enzymes. The tRNAs are used to trigger the replication, while the viral enzymes, 
which derive from the polypeptide precursor of the pol gene, are the reverse transcriptase 
(RT), a heterodimer consisting of two polypeptides (p51 / p66) which intervenes in the 
replication of the genome, the integrase (p32) which causes the integration of viral DNA into 
the cellular DNA and the protease (p10) that intervenes in the maturation of the genome. An 
independent domain of RT carries out an additional enzyme activity of specific ribonuclease 
(RNAse H) that degrades the RNA in the RNA-DNA hybrid produced during the proviral 
genome synthesis. 
 
1.4 Structure and organization of the viral genome 
 
Like all retroviruses, HIV-1 presents two genomic forms: a single-stranded RNA in the 
extracellular phase of the life cycle of the virus and a double-stranded DNA within the cell. In 
the early stages of infection, virion RNA is converted into the double-stranded DNA form by 
the RT of the virus and is then integrated into the genome of the host cell (provirus). 
The virions contain two identical copies of single-stranded RNA of approximately 9.2 Kb with 
positive polarity. The two strands are associated in numerous points along their length; in 
particular, the junction point of greater stability is located near the 5 'end of each genome. The 
role of diploidy is still obscure. 
Viral RNA presents the characteristics typical of most eukaryotic messenger RNAs: the CAP 
(m7G5'ppp5'Gmp) at the 5 'end and a tail of about 200 adenine residues at the 3' end. Also 
occasionally adenine residues can be methylated. A tRNAlys molecule is positioned near the 5 
'end of each strand and serves as a primer for the synthesis of the DNA negative filament by 
RT. 
The genomic structure of HIV-1 is shown in Figure 2. 
 
 
 
 
 
 
 
 
 
Figure 2: the genomic structure 
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Two repeated sequences, named long terminal repeat (LTR), are placed at the ends of the 
genome and flank the three major open reading frames (ORFs) of the virus: gag, pol and env 
and another six smaller ORFs: tat and rev, essential for viral replication, vif, vpr, vpu and nef 
not essential for replication, also called accessory or auxiliary genes. The presence of these 
six ORFs gives the virus an extraordinary level of complexity. 
 
1.4.1 Long-terminal repeat 
 
As in the other retroviruses, the LTR region is divided into three functionally distinct domains: 
U3 (-453 / + 1), R (+ 1 / + 98) and U5 (+ 99 / + 185) (from 5 'to 3'). 
These functional units are critical for virus integration within the host genome and contain 
promoters and enhancer elements recognized by viral and cellular transcription factors. 
The U3 region extends from the 5 'end of the genome to the site of initiation of transcription 
(+1) and contains the viral promoter, consisting of three transcription domains: the modulation 
domain, the enhancer and the core or base domain . The first portion of U3 is the modulation 
region that contains cis-acting regulator transcription elements to which many cellular factors 
are bound (i.e. AP-1 and N-FAT-1). Downstream of the modulation region is the enhancer a 
region formed, in HIV-1, by two sites of 10 bp. These sites bind the cellular factor NF-kB 
which has the function of increasing the transcription activity of the virus following the 
activation of the same factor by some cellular regulatory proteins or other viruses. At the 3 
'end of the U3 is the core containing a TATAA box region for binding to the cellular RNA 
polymerase II responsible for viral transcription; the viral transcription initiation site is 22 bp 
downstream of this region. Sites for binding the SP1 cell transcriptional factor are placed 
immediately after the TATAA box (26). 
The region R encodes a sequence of RNA that forms a hairpin (stem-loop) structure at the 5 
'end of the transcript called tat-response element (TAR). This structure binds the Tat protein 
of HIV-1, a powerful activator of viral transcription. 
The R / U5 region is located in the leading sequence of all viral transcripts. The 3 'end of the 
transcripts is defined by the R / U5 edge of the 3' LTR. 
Although the nucleotide sequences of the two LTRs are identical, retroviruses have 
mechanisms by which the 5 'LTR is used as a transcription promoter while the 3' LTR is a 
signal to add the poly-A tail, in fact signals in the U3 and R region they are recognized by 
cellular factors that add poly-A tails to the 3 'end of viral transcripts (27). 
 
1.4.2 Structural genes 
 
HIV-1, like all retroviruses, has three structural genes essential for replication, called 
respectively: gag (group specific antigen), pol (polymerase) and env (envelope). The three 
genes are organized in the genome in the order 5'-gag-pol-env-3 '. 
The gene gag represents the first ORF of the HIV-1 genome that encodes a peptide precursor 
of the internal structural proteins of the virus, of 55 kDa translated by an mRNA not subjected 
to splicing processes (unspliced) as long as the genome. 
The precursor, the polypeptide p55, is subsequently cut from the viral protease to produce the 
virid capsid protein, p24, the matrix protein, p17, the nucleocapside protein p9 and the p7 
previously described. 
The pol gene overlaps the gag gene for about 241 bp. This gene is expressed as gag / pol 
fusion protein from an unspliced mRNA as long as the genome and from the segmentation of 
this protein the viral enzymes are derived: the protease, p10, with a autocatalytic cut, the 
integrase, p32, and the etherimer p66 / p51 ie the reverse transcriptase. An independent 
domain of the RT plays a ribonuclease function. 
The env gene encodes a highly glycosylated protein precursor, gp160, translated from a 
polycistronic mRNA derived from a single splicing process (singly-spliced). The protein is 
cleaved from a host endopeptidase into two portions: the N-terminal gp120 and the C-terminal 
gp41 which form, through non-covalent interactions, the surface antigen of HIV-1, which 
mediates the entrance of the virus. Sequence comparison studies reveal a model, of the env 
sequence encoding gp120, of 5 variable regions (V1-V5) interspersed in conserved regions 
while the gp41 region is fairly conserved (28). One of these domains (V3) is highly variable 
and is the main target of neutralizing antibody activity. 
 
1.4.3 Regulatory genes 
 
The tat and rev regulatory genes control the expression of viral genes at the transcriptional 
and post-transcriptional levels. 
The first coding exon of tat is located in the central region of the viral genome between the vpr 
gene and the env gene while the second exon is superimposed on the rev reading frame 
(open reading frame) and the env gp41 (29). The Tat protein is translated from monocistronic 
transcripts, produced early in the infection, subjected to multiple spliced processes (multi-
spliced), and interacts with the TAR site at the 5 'end of each messenger. In this way Tat 
increases the levels of viral RNA by acting at the beginning of the transcription (30) or during 
elongation (31). 
The rev gene regulates the splicing and transport of transcripts from the nucleus to the 
cytoplasm (32). The two coding exons of rev partially overlap with tat exons and the rev 
protein is also translated by multiply-spliced transcripts produced in the early stage of 
infection. 
 
1.4.4 Ancillary Genes 
 
The accessory genes of HIV-1 are vif, vpr, vpu and nef. Vpr is assembled within the virion and 
although most studies have not found traces of the other three proteins in the virion, it is 
possible that small amounts may be incorporated equally. The proteins of these genes are 
mostly translated from singly spliced transcripts. 
Although several studies have been conducted on the function of these genes, many of these 
are discordant. Presumably such genes play an important role in virus-host relationships. 
It is believed that the proteins encoded by the vpr and vif genes are both involved in the 
transmission mechanism of the virus. It seems that the vpr-encoded protein also influences 
the transmission rate, facilitating the nuclear localization of the viral genome, while the protein 
produced by the vif gene seems to be essential for virion infectivity. The protein encoded by 
the vpu gene, could instead be involved in the maturation process of the viral particle, 
facilitating its exit from the host cell. 
The nef gene extends from the 3 'end of env up into the U3 domain of the 3' LTR. The 
transcription of the gene produces two precocious multiply spliced transcripts, independent of 
the rev function, one of which is monocistronic while the other is bicistronic and encodes both 
for nef and for rev (33). 
The Nef protein has many important functions among which the activation of the cascade of 
enzymes that determine the activation state of the cell, in this sense the Nef protein is 
required for an efficient replication of HIV-1. 
 
1.5 Life cycle of HIV 
 
In the replicative life cycle, shown in Figure 3, of HIV-1, an early and a late phase is 
recognized. The early phase begins with the binding of the virion both the CD4 cell surface 
receptor and the coreceptor, with consequent entry of the nucleocapside into the cytoplasm. 
The virus RT, associated with the nucleocapside, converts the RNA into DNA that is 
maintained in a nucleoprotein complex and transported within the nucleus. Here the double 
helix of DNA is integrated into the cellular genome. The late replication phase begins with the 
transcription and processing of viral RNA derived from the proviral form and ending with the 
release of new virions from the cell. 
 
   
 
Figure 3 life cycle of HIV 
 
 
1.5.1 Bonding and entry of the virion 
 
The HIV-1 attack on cells is mediated by the initial interaction between the extracellular 
domain (gp120) of the virus surface antigen and the CD4 receptor located on the cell 
membrane of T-helper lymphocytes, macrophages, dendritic cells and microgliali (34). CD4 is 
a member of the immunoglobulin family and consists of four extracellular domains (D1-D4) 
that have a similar structure to those found in other immunoglobluline families (35). Other cell 
surface receptors are implicated in the attack and entry of the virion. As already mentioned, 
among the main molecules that can act as receptors together with CD4, it is possible to 
distinguish those that function as chemokine receptors; moreover, other receptors would be 
molecules that can facilitate the infection or that may be involved in the regulation of some 
steps following viral assembly, such as the fusion between cell and cell, and those that can 
function as primary receptors in HIV infection -1 in CD4- cells. 
The existence of a CD4 co-receptor was supported by the observation that the transfection of 
human CD4 into murine cells (36) or a human glioma cell line (37) is not sufficient to allow 
entry of the virus despite the HIV-1 particles or the recombinant gp120 bind efficiently to the 
cells. In this regard, a protein called fusin (CXCR4) has been identified that, when 
coexpressed with CD4 in mouse cells, allows the fusion with cells expressing viral envelope 
proteins on the surface. In addition, antibodies against fusin block fusion in human cells that 
are normally permissive for HIV-1. This molecule belongs to the superfamily of the G protein-
coupled receptors and has a close relationship with the α-chemokine CXC family receptors. It 
is more specifically implicated in the infection of lymphocytotropic strains and is associated 
with the viral phenotype SI (Syncitia Inducing). 
Other chemokine receptors have been identified as coreceptors in the infection of 
macrofagotropic strains, in particular some cytokine receptors belonging to the α-chemokine 
group including CCR1, CCR20, CCR3, CCR5. Among these, CCR5 is considered to be one 
of the major receptors for CD4 cell infection, allowing membrane fusion and infection for the 
macrofagotropic HIV-1 strains, this receptor is associated with the NSI phenotype. Recent 
acquisitions have shown that subjects homozygous for the 32 bp deletion in the gene coding 
for the coronector CCR5 are frequently, but not always, resistant to HIV infection. This 
observation supports on one hand the hypothesis that HIV-resistant individuals do not 
express CCR5 correctly, and on the other that this molecule is one of the most important HIV 
receptors. 
Moreover, current research has developed a series of models on the possible process of 
attack of lymphocytotropic and macrophage-viral strains following binding of the CD4 receptor 
and, respectively, of CXCR4 and CCR5 receptors (34). 
Other molecules may play a primary role in regulating critical steps following virus entry and 
cell-to-cell transmission, such as the fusion of cell membranes of CD4 T cells and HIV-1-
infected monocytes and the consequent formation of syncytes . In this regard, recent studies 
have shown that the CD4 molecule is necessary but not sufficient to mediate the formation of 
syncs and that this process is regulated by the interaction between the LFA-1 adhesion 
molecule and its ICAM-1, ICAM-2 receptors and ICAM-3 present on lymphocytes (38). Finally, 
a possible receptor in the glial and neuronal cells CD4- is the glycolipid galactosyl-ceramide 
(GalC). In fact, it has been shown that the HIV-1 gp120 binds to this molecule with similar 
affinity to that of CD4, but the efficiency of the infection is lower in experimental conditions. 
(39,40). 
As already mentioned, an important factor for the understanding of the virus-receptor binding 
is the genetic variability of HIV-1, a particularly important feature since variations in the 
nucleotide sequence can determine biologically relevant structural changes in viral proteins 
by modifying their functional and immunogenic properties ( 41, 42). 
Following the recognition and binding of the target cell, the most accredited mechanism of 
entry of the virion (internalization) in most cells is the direct fusion of the cellular plasma 
membrane with the viral envelope by a process independent of pH. 
The heterodimer gp120 / gp41 is kept within the envelope, through non-covalent interactions, 
in an oligomeric complex. In the native state, that is before the binding to the cell, each 
oligomeric complex presents the leucine zipper sequences of the gp41 separated from each 
other. Afterwards, most likely the binding to CD4 or the proteolytic cut of a membrane 
protease (CD26) that recognizes and cuts the sequences in the V3 loop at the level of the 
Arg320, induces a conformational change such that the leucine zippers in the gp41 interact 
and they form a fusion domain that facilitates the fusion between the two membranes. 
Finally, one factor to consider is the different cellular tropism that distinguishes different HIV-1 
isolates from the same infected person. Central nervous system HIV-1 isolates preferentially 
grow in macrophage cultures (macrophage-like strains), whereas those obtained from 
peripheral blood mononuclear cells, stimulated with PHA and IL2, propagate better in T 
lymphocytes (lymphocytotropic strains). Blood dendritic cells and Langherans cells of the skin 
and mucous membranes also allow replication of many HIV-1 strains with different tropism. In 
contrast, follicular dendritic cells of the lymph nodes, which present the antigen to T 
lymphocytes in the lymphatic follicles can only bind HIV-1 to their surface without getting 
infected. 
 
1.5.2 Synthesis and integration of viral DNA 
 
The model for the reverse transcription of lentiviruses is similar to that proposed for other 
retroviruses and has been elucidated by analysis in cell-free systems (43). The reverse 
transcription of the genomic RNA is mediated by the reverse transcriptase (RT, p66 / p51) an 
enzyme that modulates different activities: DNA polymerase dependent RNA, DNA dependent 
DNA polymerase and ribonuclease (RNAase H) (44). 
It is activated in the cytoplasm by a signal that is not yet well identified. The synthesis of the 
first DNA strand, ie the negative polarity one, begins with the annealing of the virus tRNAlys 
at the PBS site (primer binding site) of the RNA mold that acts as primer for the RT. The 
complete double helix is formed by a rather complex mechanism. After the synthesis of the 
filament 
linear DNA is completed in the cytoplasm, the viral DNA, in the form of a nucleoprotein 
complex, migrates to the nucleus to be integrated into the genome of the host cell. Although 
both the structure and the precise composition of this preintegration complex are unknown, it 
is certain that viral DNA, integrase and matrix protein are part of this complex (45). The 
transport of the complex in the nucleus is an active process of the host cell that requires ATP 
but is independent of cell division (46). Lentiviruses have been proposed to replicate in 
differentiated non-proliferative cells in contrast to the other retroviruses. 
Integration is not a random process (48). The analysis of cellular sequences flanking the 
provirus reveals that HIV-1 is preferentially inserted in or near two classes of repeated 
elements of DNA in the human genome: L1 and Alu (49). These elements are transposons 
and show common properties with retroviruses. Thus, the preferential integration of HIV-1 
within these elements may reflect the local chromatin structure that is more susceptible to 
acquiring a transposon. In vitro analyzes of the proviral integration mechanism show that the 
intermediate for the covalently linked provirus in the cellular genome is linear and non-circular 
viral DNA. However, the circular form, which can not replicate, can be found after infection 
and can remain stable for many days as opposed to the linear form that is rapidly degraded. 
 
1.5.3 Expression and regulation of viral genes 
 
The control of genome synthesis is complex and involves the combined action of viral agents 
acting in cis, viral transactivators and different cellular proteins. In the nucleus, the integrated 
proviral DNA is transcribed from the cellular RNA polymerase II to produce RNA precursors of 
the same length as the genome. 
The expression of the provirus leads to the formation of three classes of transcripts: genomic 
RNA for viral progeny, messenger RNA for translation into the cytoplasm of polyproteins Gag 
and Gag-Pol and precursors for over 30 alternatively spliced messenger RNAs that are 
translated into the cytoplasm for produce env glycoproteins and accessory proteins (50). 
Initially in the absence of the Tat transactivator, the viral specific transcription level is low. The 
precursor RNAs are transported through a Rev-independent transport mechanism but before 
transport the spliceosomes remove the introns from the multiply spliced transcripts that are 
then translated to produce the regulatory Tat, Rev and Nef proteins that return to the nucleus. 
As the transcription proceeds, Tat levels increase and consequently the transcription activity 
itself increases. As Rev also accumulates, the precursor RNAs are transported to the 
cytoplasm by a Rev-dependent mechanism 
does not require splicing before transport. In this phase, unspliced and singly spliced viral 
mRNAs are translated into Gag, Pol, Env, Vpr, Vpu and Vif proteins in the cytoplasm. Rev, 
therefore, acts as a molecular chaperone interacting with the RRE sequence present in all the 
transcripts in correspondence of the env gene. 
 
1.5.4 Assembly and release of the virus 
 
The first event in the assembly of virions is the interaction between the precursor polypeptide 
of the gag gene (pr55), the polypeptide precursor Gag-Pol (Pr160) and the viral genome to 
produce a nucleoprotein complex. This process can occur in the cytoplasm or on the 
membrane. The maturation of the Gag polyproteins during assembly is mediated by the 
protease domain in Pr160 to produce a mature nucleocapsid. At the same time, the gp120 
and gp41 are inserted into the plasma membrane and, following interaction of the matrix 
protein with the cytoplasmic tail of gp41, the viral nucleoprotein complex extrudes or buds 
through the membrane to produce a 
mature virione. The precise mechanism of budding is unknown. 
 
1.6 Role of viral enzymes 
 
1.6.1 Reverse transcriptase   
 
Retroviruses have a reverse transcriptase that catalyzes the synthesis of proviral DNA using 
viral RNA as the template. This process is complex, but 
in short, it consists of three catalytic passages: 
1) The production of a complementary DNA chain from the genomic RNA, which involves the 
formation of a RNA-DNA hybrid. 
2) The removal of the RNA mold (by the ribonuclease activity of the RNase H domain of the 
RT), leaving the DNA with a single strand. 
3) The synthesis of a second DNA chain, complementary to the first. 
The double DNA chain is subsequently integrated into the chromosomal DNA by integrase. 
The proviral DNA becomes the template for the transcription of viral RNA for the formation of 
new viral particles. 
The reverse transcriptase is a heterodimer composed of the subunits p55 and p66 (51) 
The polypeptide contains the DNA polymerase domain (440 amino acids) and the RNase-H 
domain (120 amino acids). The RNase-H domain is located in the C-terminal region of the 
p66 subunit. Although the p51 and p66 subunits have an identical amino acid sequence, they 
occupy completely different relative positions. In the p66 subunit there is a split in which the 
RNA-DNA hybrid takes place. This structure is absent in the p51 subunit, which does not 
catalyze polymerization. The acid residues (aspartic acid) in position 110, 185 and 186 confer 
the polymeric activity. 
RT activity is an essential component of HIV-1 replication. 
A particular feature of the enzyme is the low degree of accuracy in the incorporation of the 
bases, which is fundamental for the continued survival of the virus. That is, the RT enzyme 
has no 'proof reading' capability and, compared to other DNA polymerases, has a higher error 
frequency. This is the major factor in the generation of mutations in the viral genome. The 
replacement of a nucleotide can however encode the same amino acid (synonymous 
mutations), or it can lead to the introduction into the protein of a different amino acid (non-
synonymous mutation). The amino acid change can lead to a modification of the structure and 
some cases of the function of the protein. 
 
1.6.2 Protease 
 
The HIV-1 protease is an aspartic protease that cuts the nascent polyproteotic complex 
during viral replication. The enzyme is composed of two identical 99 amino acid polypeptides, 
with a proline at the N-terminal end and a C-terminal phenylalanine. Each monomeric subunit 
contains two regions with β-sheets structure and a small α-helical region. 
The region comprising the active site extends from methionine to position 46 
to the lysine in position 55 (52). 
The study of a new class of drugs, protease inhibitors, has led to a growing interest in the 
mechanism of action of the protease and its role in HIV infection. In fact, the maturation 
events catalyzed by the enzyme are essential for the formation of infectious virions. 
 
1.6.3 Integrase 
 
Similarly to all retroviruses, replication processes depend on the integration of the viral 
genome into the chromosomes of the host cells. The HIV-1 integration processes are 
performed by viral integrase after a series of DNA cuts and subsequent re-joining reactions. 
In recent years PCR-based assays have been developed that can measure viral integration 
rate in cell systems and allow the identification of compounds capable of specifically blocking 
integrase in vivo. 
 
 
 
 
 
1.7 Dynamics of viral replication 
 
The knowledge of the viral replication trend was initially based on limited virological and 
immunological observations (p24 antigen and CD4 lymphocyte counts) and on the clinical 
progression of the disease. 
My colleagues and I have shown that HIV-1 replication is high and continuous at different 
stages of infection and that viral load can be used as a prognostic indicator of AIDS 
development (53). In particular, the plasma levels of the virus are constant and this implies 
that the virus is produced and eliminated with the same frequency, ie that the system is in 
equilibrium. 
Two important studies published in 1995 provided the first analysis of viral dynamics through 
the use of antiretroviral therapy (54, 55). They reported an exponential decline in plasma 
viremia within two weeks of initiation of antiretroviral therapy. The decrease in plasma 
viraemia after treatment reflected the combination of two separate effects: the elimination of 
plasma-free virions and the decrease in the cells that produce the virus, resulting in the 
blocking of new infections. 
The average life span of the virus was established by observing the progression of plasma 
viral decline, assuming that viral replication was completely stopped during antiretroviral 
therapy. The average life of the virus was about 2 days. In particular, the production of HIV-1 
has been estimated at around 0.68 x 109-1.1 x 108 virions per day (54, 55). 
In 1996 Perelson and colleagues, using mathematical models and non-linear regressions, 
calculated the amount of virions eliminated daily and the average life of virus-producing cells 
(56). The average life of the virus was estimated at 6 hours and therefore the production of 
virions was 10.3 x 109 virions per day, 15 times higher than previous estimates. 
 
1.8 Genetic variability of HIV-1 
 
One of the most striking features of the HIV-1 virus is its extreme genetic variability that 
manifests itself not only in the isolates of different individuals, but also in the different isolates 
of the same individual during the course of the infection. 
The molecular bases of viral variation are due to the high frequency of error in the 
incorporation of nucleotides by the RT. These modifications are the result of mutations in viral 
genes that code for these enzymes and derive from the high error frequency of viral 
retrotranscrypt, of about 3x10-5 substitutions per replicative cycle (57). Considering that the 
HIV-1 genome is about 104 bases and that the total viral load in subjects with HIV-1 infections 
is 109-1010 virions, the probability that in a given patient can occur every single possible 
nucleotide substitution is around at 104-105 times in one day (58). These data suggest the 
rapid onset of a genetic divergence within the viral population, generating within each HIV-
infected individual a genetically different 'quasispecies', rather than a single viral population. 
 
1.8.1 Mechanisms of viral variation 
 
Viral variation is due to three possible mechanisms: 
Mutation 
The fundamental characteristic of the continuous evolution of HIV-1 is the low degree of 
accuracy in RT polymerization. This enzyme has a high error rate and has no 'proof-reading' 
activity and therefore proves to be the most responsible for generating mutations in the HIV-1 
genome. These changes are usually the result of point mutations that can be divided into two 
categories: substitutions and insertions or deletions. 
a) Replacement is the change of a nucleotide with a different one during viral DNA formation. 
The substitution may or may not involve coding for a new protein by providing a different 
'fitness' to the virus. 
b) Insertion and deletion are additions or deletions of one or more nucleotides. Insertion or 
deletion of nucleotides may alter the 'frame' of the mRNA reading. 
In particular, the structural gene env seems to possess a greater degree of variability 
compared to other regions of the HIV-1 genome (46-50). Analyzing sequences of env coming 
from the same patient with HIV-1 infection it is possible to highlight the presence of 
'quasispecie', that is of closely related but distinct viral variants, which differ from each other 
for about 2-5% of the sequence of env (63-65). Considering instead isolates coming from 
different geographic areas, the genetic variability in env can reach values of 20-30% which 
decrease to 6-19% for isolates coming from the same area (59-62, 66-69). For this reason, 
the env gene represents the most frequently used gene in lithogenic analyzes, since its high 
rate of variability makes it possible to more precisely evaluate the genetic distances between 
different isolates. 
Recombination 
 
Another mechanism of viral variation derives from recombination. This event occurs 
frequently during retrotranscretion, as there are two genomic RNA chains in each virion. The 
HIV-1 RT enzyme has the ability to transfer the synthesis of a DNA chain from one template 
to another. 
 
Superinfection and recombination 
 
Retroviral recombination requires simultaneous infection of the same cell by two different 
strains (ie superinfection) and the subsequent integration of two parent proviral generations in 
the same nucleus. 
Simultaneous expression and assembly of viral RNA generates a population of first 
generation heterozygous viral particles. These particles in turn can infect new host cells and 
be retrotranscribed. In this reaction, the reverse transcript can jump from one template to 
another. This phenomenon is what is defined as strand-switching activity of the HIV-1 RT. In 
this way a second chimeric generation of provirus can be formed. The viral particles produced 
by the second generation will contain the recombinant forms of viral RNA (3). 
 
1.9 Pathogenesis and natural history of infection 
 
The main route of infection transmission is represented by homosexual and heterosexual 
relationships and the probability of infection depends on the number of sexual partners and 
the different sexual practices (70). The virus is transmitted through genital secretions, both 
female and male, and blood (cells, plasma and coagulation factors) (71). A strong 
transmission incidence is registered among drug addicts due to the use of contaminated 
needles. The virus can be transmitted from the infected mother to the child either by 
transplacental route or through childbirth following exposure to the genital tract or following 
breastfeeding. On the other hand, non-sexual personal contacts, exposure to saliva (72), 
contact with urine (73) and exposure to insects (74) have never been directly implicated in the 
transmission of HIV. 
Little is known about the early events following HIV-1 infection. The initial target cells are most 
likely those of the monocyte-macrophage dendritic line such as Langherans cells and 
lymphocytes in the genital and rectal features. Infection of new cells in the blood and 
dissemination occurs through the free virus or by cell-cell interaction. The major targets of 
HIV-1 are the lymphoreticular system, the hematopoietic system and the nervous system. 
Target cells that are critical for immunopathogenesis are dendritic cells, CD4 T lymphocytes, 
and monocyte macrophages. 
The pathogenesis of neurological diseases of HIV-1 is also unknown. The predominant cells 
that are infected within the nervous system are monocytes and macrophages. Within the 
nervous system, infected macrophages are likely to release monochins, the alpha factor of 
tumor necrosis or the beta factor of transformation, and viral proteins that are toxic to neural 
cells. 
Despite the devastating effects of HIV-1 on host immunity, infected individuals develop a 
humoral and cellular response against HIV-1-associated antigens. Neutralizing antibodies are 
produced by most individuals (71) and some researchers have noted a correlation between 
disease progression and low titers of neutralizing antibodies (74). Envelope glycoproteins are 
the major targets for neutralizing antibodies and the different epitopes on gp120 have shown 
the ability to generate neutralizing antibodies in experimental animals. Some of these are in 
hypervariable regions (75) while others are in conserved areas. The reactivity to the gag gene 
products sought by the enzyme immunoassay (ELISA) seems to reflect the progression of the 
infection. In fact the decrease of circulating anti-p24 antibodies and the appearance of 
circulating p24 antigens often correspond to the decrease in CD4 T cells and are associated 
with the progression of immune dysfunction and the development of AIDS (76, 77). 
Also the cellular response is directed against HIV-1 antigens, in fact, cytotoxic T lymphocytes 
react with the env, pol, gag and regulatory gene products. 
The typical clinical course of HIV-1 infection has been clearly defined following the isolation of 
HIV-1 from patients with AIDS or clinical signs preceding AIDS (120). It includes a phase of 
primary infection, with an acute syndrome of varying severity, a prolonged period of clinical 
latency and a final stage of disease characterized by an increase in susceptibility to 
opportunistic infections and neoplastic diseases (79). A peculiar feature of HIV-1 infection is 
the wide variability that can be found between one patient and another in the progression of 
the disease. In particular, what varies considerably is the duration of the clinical latency 
between the different infected persons (80) and the progression to AIDS, which occurs after 
an average period ranging from eight to ten years (81, 82), although the decline 
immunological and clinical is much more precocious in a significant proportion of patients. In 
this regard, it is interesting to note that in a small number (from 2 to 5%) of people infected 
with HIV-1 (long-term non-progressor subjects) the clinical latency phase and the 
immunocompetence stage extend over a period of much longer time (75, 83). 
In recent years there has been much debate whether CD4 T cell depletion and AIDS 
pathogenesis are the result of direct cytolytic effects of HIV-1, of T-cell apoptosis by non-
specific activation processes or are due to dysregulation phenomena in the production of 
cytokines and autoimmunity events. 
According to biological and immunological molecular tests, the pathogenesis and progression 
of HIV-1 infection is currently described as a multi-stage process (84), in which a multitude of 
viral and host factors are potentially implicated. been studied in recent years in vitro and in 
vivo (84.85). 
In this complex scenario, different biological and molecular outcomes (86) have highlighted 
the correlation between viral replication and infection progression by studying the association 
between clinical stage and viral load in progressing patients (representing the majority of 
people infected from HIV-1) and the dynamics of viral activity during the natural course of the 
disease. 
 
1.9.1 Genetic complexity of the pandemic 
 
The increasing availability of sequences of the entire HIV-1 genome from different continents, 
made possible by new assays (Heteroduplex Mobility Assay) and new methodologies (PCR-
long-range and automatic capillary sequencing), has greatly enriched the sequence database 
of HIV (HIV Sequence Database, Los Alamos, New Mexico, USA) and has allowed the study 
of the changes occurred in the last decade in the distribution of distinct subtypes in different 
geographical areas (3, 4). The sequences from different viral isolates have in fact been 
classified over time into groups and subtypes based on their phylogenetic relationships. 
Each subtype includes sequences that are equidistant to each other and to be assigned to 
each subtype the strains must be similar to each other and different from other subtypes 
throughout the length of the genome. To study the evolutionary distances of the sequences, 
phylogenetic analysis is used. In particular these distances are represented by phylogenetic 
trees. They are two-dimensional graphs made up of branches connected to each other via 
nodes. The terminal nodes, or extremities, represent the current (or contemporary) taxa, while 
the internal nodes represent the ancestral ones. The phylogenetic relationships are defined 
through the tree topology: the distribution of the nodes and the length of the branches that 
connect them provide indications on the evolutionary divergence between the different taxa, 
allowing to identify monophyletic groups or evolutionary lines (11). 
To date, three groups have been defined: M (Major), O (Outlier) and N (New). Within the M 
group, 11 subtypes have been classified (A, B, C, D, E, F, G, H, I, J and K). The strain E, 
previously identified on the basis of the env gene as a separate subtype, was found to be a 
recombinant based on the entire genome whose genes gag and env belong respectively to 
subtypes A and E. Also subtype I, initially identified in a limited number of env gene 
sequences has turned out to be a recombinant form in which the gag gene is a sequence 
composed of parts of subtype A and G, while env is a sequence distinct from the others, ie I 
(3, 4). 
In addition to the subtypes identified to date, the so-called Recombinant Circulating Forms 
(CRF) are present in different geographical areas. Six have been officially classified (CRF 01-
06) and 3 CRF 07-09) have been recently identified  (4, 5).  
Among the recombinant forms CRF 01AE and CRF_02AG play an extremely important role 
as they circulate at high frequency respectively in South East Asia and in sub-equatorial 
Africa (3-5). 
One of the major characteristics of the human immunodeficiency virus is its extremely high 
genetic variability. This heterogeneity is the result of both the high error rate of reverse 
transcriptase (6), which governs the evolution of subtypes, generating the high inter-subotypic 
and intra-subtypical variability, and the rapid turnover of virions in individuals infected with 
HIV. (7, 8). Furthermore, the reverse transcriptase enzyme has recently been recognized as 
highly recombinogenic (3) and this characteristic appears to be the main cause of CRF 
generation. The recombination event requires the simultaneous infection of a cell by two 
different viral strains (superinfection), followed by the assembly of an RNA transcript coming 
from each provirus within the heterozygous virion. After the subsequent infection of a new cell 
the reverse transcriptase, through a strand-switching mechanism between the two RNA 
templates, can generate a new retroviral DNA sequence that will be recombinant between the 
two parental genomes (9, 10). 
These mosaic viruses are defined as recombinant and this is supported by the fact that 
distinct recombination points can be recognized between genomic regions belonging to 
different subtypes (87, 88). Today it is clearly established that recombination is a relatively 
common occurrence that occurs between different HIV subtypes where high prevalence 
cocircolane occurs. Recombination generally occurs between strains belonging to different 
subtypes, but it can also occur between strains belonging to the same subtype. 
In 1999 the further increase in the complete genomic sequences of HIV-1 (89, 90), together 
with epidemiological studies on its variability and its geographical distribution (91), allowed to 
reconsider the contribution to the pandemic of the different variants and especially of the 
recombinant forms (92). 
On this basis the most recent classification was introduced (92), which provides that: 
1) the recombinant forms of HIV-1 with high prevalence in certain populations and geographic 
areas are called "Recombinant Circulating Forms" (CRF); 
2) sub-sub-types can be defined on a geographical basis; 
3) at least three complete genomes must be isolated in order to identify a 'new' subtype, a 
sub-subtype, and a CRF. 
If the genome contains sequences originating from more than two subtypes, the letters are 
replaced by "cpx", which stands for "complex". 
The designation of the subtype represented a formidable epidemiological molecular marker to 
follow the evolution of the HIV-1 pandemic. 
On the basis of current knowledge it seems clear that the various subtypes, sub-subtypes and 
CRFS are the result of specific epidemiological events / phenomena. 
The predominant viral forms in the global epidemic are subtypes A and C, followed by 
subtype B and recombinants CRF02_AG and CRF01_AE (3, 93, 94). 
In Africa the subtypes A and C and CRF02_AG are the most common, however in this 
continent are present all the groups (M, O and N) and all the subtypes, according to the origin 
of the epidemic. The strains belonging to groups O and N were originally identified in Africa, 
were not classified into subtypes and some recent reports suggest their penetration in Europe 
and the United States (4). In Southern and Eastern Africa the subtype C (12, 95) 
predominates, in West and Central West Africa the majority of the viruses are CRF02_AG 
(13). In the United States, Canada, Europe and Australia, subtype B is largely the most 
represented, although recent studies have shown the presence of many other subtypes 
belonging to group M and group O viruses (96-103). Subtype B predominates in South 
America, however subtypes F and C have been identified (104-106). In Asia there are many 
different subtypes: in India the C and A strains are prevalent today, while in South East Asia, 
in addition to the B that probably represented the first subtype, the subtype C and the 
CRF01_AE circulate. In China, further CRFs have recently been identified: CRF07_BC and 
CRF08_BC (14, 15). 
The exact prevalence of recombinant strains is not known in detail, as the studies conducted 
are limited to some regions and even in these areas they may not be representative of their 
real distribution. In Africa, preliminary data show that the gag / env discordance, a 
recombination index, in the samples analyzed can vary from 10 to 40, in agreement with the 
studied countries or regions (13, 107-111). The recombinant strains detected by these studies 
are related to the subtypes that co circulate in these regions: for example in Nigeria, where 
the subtypes A and G circulate to the same extent, the recombinants found are CRF02_AG 
(107, 108). Similarly, in the Democratic Republic of the Congo, where many subtypes 
circulate, a high prevalence of recombinants was found among the various subtypes (112). 
The global distribution of the different forms of HIV-1 is a dynamic process. The likelihood of 
detecting new recombinant forms will increase with increasing HIV-1 variants that will 
circulate together in different parts of the world. The patterns of the new mosaicisms will 
become increasingly complex as the recombination will involve viral strains which are in turn 
the result of one or more recombination events. Mosaic viruses of CRF02_AG have already 
been observed in some African countries (113). 
The worldwide distribution of distinct HIV-1 subtypes has a major impact on epidemiology, 
pathogenesis, diagnosis, treatment and prevention of infection. 
It has long been hypothesized that the presence of different subtypes in specific areas has 
important implications for pathogenesis. The subtypes differ in the number or conformation of 
regulatory elements such as the binding site for NF-kB and the loop of the regulatory region 
TAR of the genomic RNA; this suggests that this represents respectively both a replicative 
advantage and a greater response to the pro-inflammatory cytokine TNF-α than an up-
regulation of tat-mediated transcription (114-116). On the side of the structural genes the env 
gene has been studied with particular reference to the use of the coreceptors by the different 
subtypes. These studies demonstrated important differences between the different subtypes 
in coreceptorial use and consequently in cell tropism. The ability to selectively use specific 
coreceptors and the ability of strains to adapt in vivo may influence the ability of viral 
'quasispecies' to colonize new cell types in the long term and may reflect a different course of 
the disease's natural history (117). 
The recent estimates of the evolution of the pandemic in the world indicate that heterosexuals 
will play a predominant role among the categories at risk of contracting HIV infection (118). 
However, in both Southeast Asia and Eastern European countries flourishing local economies 
based on narcotics trafficking are responsible for major outbreaks (119-121). 
These epidemics showed two characteristics, perhaps associated with each other, worthy of 
great interest: a) the emergence and rapid spread of new recombinant strains characterized 
by complex mosaicism in which the gene transcriptase shows numerous recombinations and 
b) the extraordinarily low genetic diversity of HIV-1 intrapazient characterizing these new 
infections when compared to other parenteral HIV-1 outbreaks (pediatric nosocomial 
infections, an infection in a Scottish prison, infections in Australian hemophiliacs) (3). The 
factors influencing these phenomena are not clarified. Although rapid diffusion of the 
'founding' strain (founder), early detection of the virus after transmission and exposure of 
these subjects to multiple viruses have been reported, RT mosaicism has been hypothesized 
viral implies a reduced processivity and an alteration of affinity for the nucleotides to be 
incorporated, that is a decreased frequency of error in the retrotranscription. 
The relationship between specific subtypes and specific disease courses remains largely to 
be clarified. Although studies conducted in Thailand showed that CD4 cell decline, AIDS 
progression time and survival time were similar in groups of subjects infected with B strain 
compared to those with CRF01_AE (122, 123), others Studies conducted in Africa suggest 
that infection sustained by C strains results in higher RNA levels and lower CD4 lymphocyte 
counts than infections sustained by subtypes A and D (124, 125). In this regard, new 
prospective studies are required in seroconverted subjects to clarify the role in disease 
progression of different subtypes and in particular of recombinant strains such as CRF02_AG 
which, based on available epidemiological data, seem to have a selective advantage to 
transmission in Nigeria ( 5). 
Molecular methods (RT-PCR, branched DNA and Nucleic Acid Sequenced-Based 
Amplification) developed in the industrialized countries for the measurement of plasma HIV-1 
viremia, which is used both for the evaluation of disease progression and for monitoring 
response to therapy, used subtype B and showed some limitations in the detection of non-B 
subtypes (126-129). Although new versions of these essays have recently been introduced, to 
date it is not known their ability to detect subtypes that circulate at low frequency in 
industrialized countries (F, H, J and K) and in particular the CRFs that are acquiring a 
important role in the epidemic in Africa and South East Asia and that have recently been 
detected in Europe (3). 
 
1.10 Laboratory diagnosis of HIV infection 
 
The laboratory diagnosis of HIV-1 infection is based both on the determination of virus-
specific antibodies and on the detection of viral antigens and / or viral nucleic acids, as well as 
on virus isolation. The serology diagnosis is used for large-scale screening surveys and has 
continuously improving levels of sensitivity and specificity. The majority of those infected with 
HIV produce specific antibodies within 6-8 weeks of infection. The period of time between the 
onset of infection and the production of antibodies is called the "serology window". However, 
in some cases, the appearance of antibodies may occur within 6 months of infection. Once 
the anti-HIV antibodies appear, they persist throughout life, especially those directed against 
envelope proteins (env). The anti-p24 and anti-env antibodies (gp41 and gp160) are the most 
frequently detected in the early stages of seroconversion. 
The isolation of the virus and the search for viral components (genomic RNA, proviral DNA 
and viral antigens) is essential . For example, the research of proviral DNA is particularly 
useful in the early stages of infection (serology window) and in the diagnosis of vertical 
transmission of infection, when the presence of anti-HIV antibodies transmitted from the 
mother to the newborn does not allow a reliable serological diagnosis (9-12 months from 
birth). Furthermore, the quantitative determination of viral DNA gnomic RNA has proved to be 
a particularly reliable virological parameter for monitoring the progression of infection and 
antiretroviral treatment response. Finally, the evaluation of plasma viral load is an important 
prognostic parameter for the evaluation of survival and the probability of vertical transmission 
of the virus. (130, 131) 
 
 
1.10.1 Serological diagnosis 
 
Since the discovery, in the early eighties, of human retroviruses and of the etiological 
relationship between human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) and 
acquired immunodeficiency syndrome (AIDS), investigations serological tests for specific 
antibodies have represented, and still represent, the fundamental approach to virological 
diagnosis of HIV infection. 
Since HIV infection soon reached epidemic proportions, it soon became necessary to identify 
new diagnostic systems that would allow for the accurate and rapid screening of an ever-
increasing number of sera. Immunoenzymatic methods (ELISA) soon became the main tool 
for the detection of anti-HIV antibodies, thanks to their speed and ease of execution. In 
addition to improving the technical characteristics of ELISA assays, linked to the introduction 
of automated systems, their diagnostic efficiency has been improved thanks to the use of 
recombinant and synthetic antigens, which have allowed to increase the specificity. The use 
of recombinant antigens and / or synthetic peptides has also made it possible to address the 
problem of the diagnosis of infection with HIV-1 strains not belonging to the main subgroup 
(main, M), but belonging to the O (outlier) subgroup, and from HIV-2 strains. 
Nonetheless, false positive results can be obtained. Therefore, the development of 
confirmatory assays that guarantee the specificity of the reaction between viral antigens and 
antibodies present in the serum remains an essential priority. The method known as Western 
Blot is the most widely used confirmatory test used in the diagnosis of HIV infection. 
Screening essays 
Rapid assays have been introduced for the screening of anti-HIV antibodies in order to have 
diagnostic tools even in poorly equipped environments, such as small hospitals or first aid 
services, or frankly inadequate, such as medical centers in countries in development, where 
the acquisition and maintenance of expensive and delicate equipment for automated 
diagnosis, such as those required for ELISA systems, are impractical. The main characteristic 
of these essays is the extreme simplicity and speed of execution and the visual reading of the 
result. Therefore, any positive result obtained with a screening method must be rechecked 
and then submitted to a confirmatory test. 
 
 
1.10.2 Molecular diagnosis 
 
PCR and early diagnosis 
 
In the molecular diagnostics of HIV-1 infection the first assay introduced was represented by 
gene amplification by polymerase chain reaction (PCR) for the research of the proviral DNA 
integrated in the infected cells. This was followed by a reverse transcriptase-polymerase 
chain reaction (RT-PCR) assay for the detection and quantification of viral RNA in plasma by 
amplification of cDNA obtained in vitro following RNA sequencing retrotranscretion. The PCR 
reaction for the identification of HIV proviral DNA is usually carried out on DNA extracted from 
PBMC obtained from the peripheral blood of the test subjects. (132) Several regions of the 
genome can be amplified, but the most frequently used one as a target for PCR or RT-PCR 
reactions, it is represented by the gag gene which is one of the most conserved genomic 
regions.  
In this context the use of rapid molecular techniques becomes fundamental: in particular the 
real-time PCR technique. Real-time PCR is a  developed technique that, using fluorescent 
probes involved in the gene amplification process, allows the measurement of the polymeric 
chain reaction of a selected genomic segment in real time, significantly reducing investigation 
times. All this is possible because the progression of the polymeric reaction is associated with 
the increase in the fluorescence signal. Real-time PCR assays can be performed using 
different methods: SYBR Green, TaqMan, FRET and Beacon. In particular, the TaqMan 
method  uses probes consisting of a short nucleotide sequence with covalently linked two 
fluorescent molecules: at the 5 'end a reporter (R) and at the 3' end a quencher (Q).  
The short distance between the two fluorochromes causes the emission of the reporter 
molecule to be damped, if not completely inhibited, by the quencher. During the amplification 
reaction using the TaqMan method, the primers and the probe adhere to the DNA, binding to 
the specific target sequences. During the polymerization phase, the Taq polymerase, thanks 
to its 5'-exonuclease activity, removes and clasps the probe. This separation promotes the 
physical removal of the reporter from the quencher, resulting in the emission of a 
characteristic fluorescence by the R, later captured by the instrument (133). 
During each cycle, the device detects the emitted fluorescence, reporting it in a graph 
"Fluorescence intensity / Cycles". 
As the reaction progresses, the signal can be increased: it is directly proportional to the 
number of R molecules released in that cycle and, consequently, reflects the quantity of 
amplification products (133, 134). 
In the first cycles the signal is very weak and can not be distinguished from the background 
(background signal), but with the gradual accumulation of the products it increases, initially 
with an exponential trend, until it stabilizes in a plateau phase (Figure 8). The saturation stage 
is the same for the curves of all the samples examined and is due to the exhaustion of 
primers, reporter or dNTPs; also the number of polymerases could prove to be limiting. The 
curves are separated in the growth period: this reflects differences in the initial accumulation 
of new DNA molecules. These differences are quantified by comparing the number of cycles 
required by a curve to reach a certain (reference) level of the fluorescence signal (threshold). 
The number of cycles used to reach the threshold is defined as the value of Ct . In this way, 
through the Ct value, it is possible to make considerations not only of a qualitative nature, but 
above all of a quantitative nature. 
The introduction of this PCR method in addition to allowing an extreme rapidity of execution 
(results in less than 3 hours, compared to 6/10 hours of a PCR) brings with it numerous 
advantages including the high sensitivity, specificity ( due to the use of very short but highly 
specific sequence probes) and reproducibility (134). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Real-Time PCR curve 
 
Dosage of viral load 
 
The availability of effective antiretroviral therapies for the treatment of HIV-1 infection 
necessitated monitoring of HIV infection and response to therapy. The most widely used viral 
replication surrogate marker is the quantitative determination of the plasma viral load (viral 
load) by plasma genomic HIV-RNA quantification. In fact the amount of plasma HIV-RNA 
correlates with the number of viral particles released in the plasma and, therefore, reflects the 
level of viral replication in the patient. Therefore, the reduction in viral load during therapy 
documents the response to treatment. If the decrease in viral load is a sign of control of the 
replication of the virus by the treatment, an increase in it may instead be considered in most 
cases an indication of poor efficacy of therapy, often due to the emergence of resistant HIV-1 
strains to antiretroviral tarmacs. Therefore, the assay of plasma HIV-RNA levels is  essential 
for individual optimization of antiviral treatment. (135)  
 
Resistance diagnosis 
 
Two principal commercial systems for genotyping analysis were available (ViroSeq HIV-1 
genotyping system, Applied Biosystems, CA and Trugene HIV-1 genotyping kit, Visible 
Genetics, which was phased out in 2014). Alternatively, the assay can be performed in 
specialized laboratories through homemade methods. The obtained data are then analyzed 
by comparison of the nucleotide sequence obtained with a reference sequence of HIV-1, 
subtype B, using an alignment software. 
These methods of identification of specific  mutations present in RT and PR (both commercial 
and developed in specialized centers) are now widespread and allow to obtain in a short time 
data on the presence of drug-resistant HIV strains, which are of considerable assistance at 
the clinical level. However, the frequent presence of complex mutation profiles and the 
possibility of cross-resistance induced by single mutations between different classes of 
tarmacs often make interpretation of the results difficult. In this regard, it has become 
necessary to develop systems for interpreting sequence data. 
Virtual phenotypic analysis is a system of interpretation of sequencing results developed 
using the genotypic sequence obtained from a given patient to predict the level of phenotypic 
resistance. Data from a patient's genotypic analysis are evaluated "virtually" based on data 
from the phenotypic analysis of many other patients collected in a large database. 
Thanks to the availability of resistance tests, therapeutic monitoring of patients with HIV 
infection is now easier, even if the interpretation of the results obtained with these essays is 
not always so immediate, and their use still requires an overall assessment of the patient's 
clinical situation. 
 
NGS 
 
Next-generation sequencing (NGS) technologies using DNA, RNA, or methylation se‐ 
quencing have impacted enormously on the life sciences. NGS is the choice for large-scale 
genomic and transcriptomic sequencing because of the high-throughput production and 
outputs of sequencing data in the gigabase range per instrument run and the lower cost 
compared to the traditional Sanger first-generation sequencing method.(136). 
Given the extreme variability of the human immunodeficiency virus (HIV) and its ability to 
replicate as complex viral populations, HIV variants with reduced susceptibility to antiretroviral 
drugs or with specific coreceptor tropism (CCR5 and/or CXCR4) may be present as minority 
members of the viral quasispecies. The sensitivity of current HIV genotypic or phenotypic 
assays is limited, and thus, these tests usually fail to detect low-abundance viral variants. 
Next-generation (deep) sequencing (NGS) produces an enormous amount of information that 
allows the detection of minority HIV variants at levels unimaginable using standard Sanger 
sequencing. NGS technologies continue to evolve, opening new and more affordable 
opportunities to implement this methodology in clinical laboratories, and HIV is not an 
exception. The ample use of a battery of more effective antiretroviral drugs, together with 
careful patient monitoring based on HIV resistance testing, has resulted in HIV-infected 
patients whose disease is usually well-controlled. The vast majority of adherent patients 
without detectable resistance become virologically suppressed; however, a subset of these 
patients with undetectable resistance by standard methods may fail antiretroviral therapy, 
perhaps due to the presence of minority HIV-resistant variants. Novel NGS-based HIV assays 
with increased sensitivity for identifying low-level drug resistance and/or coreceptor tropism 
play an important role in the success of antiretroviral treatments (137). 
 
1.11 Epidemiology 
 
1.11.1 Worldwide 
 
The number of people living with HIV (PLHIV) in the world at the end of 2015 is estimated to 
amount to 36.7 million (of which about 1.8 million individuals under the age of 15), compared 
with 2.1 million new cases during the year (150,000 in children under 15). 
Globally, HIV has a prevalence of 0.8% on the population. Italy in particular stands at 0.4%, 
below the world average 
The latest update in June 2016 (fig 5) indicates that as many as 18.2 million people worldwide 
are currently being treated with antiretroviral therapy, a sensational figure considering it has 
doubled over the previous 5 years and leaves presage for future scenarios where almost the 
entire population infected can be subjected to antiretroviral therapeutic treatments in order to 
improve its quality and lifespan (138). 
 
 
 
  
Figure 5 number of people infected and treated   
The dominant HIV subtype in the Americas, Western Europe and Australasia is subtype B. As 
a result, the great majority of HIV clinical research has been conducted in populations where 
subtype B predominates, despite this subtype representing only 12% of global HIV infections. 
In contrast, less research is available for subtype C, although nearly 50% of all people living 
with HIV have subtype C. It is very common in the high prevalence countries of Southern 
Africa, as well as in the horn of Africa and India. The greatest diversity of subtypes is found in 
Cameroon and the Democratic Republic of Congo - the region where the HIV-1 epidemic 
originated. But migration and population mixing means geographical patterns in the 
distribution of subtypes are changing over time, and predicting transmission patterns in 
particular areas has also become more difficult.(139). 
 
1.11.2 AFRICA and MALAWI 
Malawi’s HIV prevalence is one of the highest in the world, with 9.2% of the adult population 
(aged 15-49) living with HIV. An estimated one million Malawians were living with HIV in 
2016 and 24,000 Malawians died from AIDS-related illnesses in the same year. The Malawian 
HIV epidemic plays a critical role in the country’s low life expectancy of just 57 years for men 
and 60 for women.  
Over the last decade, impressive efforts to reduce the HIV epidemic have been made at both 
national and local levels. In 2016, 70% of people living with HIV in Malawi were aware of their 
status, of which 89% were on treatment, of which 89% were virally suppressed. This equates 
to 66% of all people living with HIV in Malawi on treatment and 59% of all people living with 
HIV being virally suppressed.   (140,141) 
 
New infections have dramatically declined from 98,000 new infections in 2005, to 36,000 in 
2016. Malawi has also witnessed a reduction in HIV infections among children. There were 
4,300 new pediatric infections in 2016, compared with 16,000 in 2010.  
Malawi’s HIV epidemic is generalized, which means it affects the general population as well 
as certain high-risk groups. Unprotected heterosexual sex between married or co-habiting 
partners accounts for 67% of all new HIV infections, while unprotected casual heterosexual 
sex accounts for 12%. Beyond this, several populations groups such as adolescent girls and 
young women, sex workers and men who have sex with men are particularly vulnerable to 
HIV. 
The Malawian HIV epidemic varies greatly across the country. HIV prevalence and density is 
high in the urban districts of Lilongwe, Blantyre and Zomba and in the southern region of the 
country. (142-143) 
 
1.12 HIV/AIDS Treatment 
 
1.12.1 Therapeutic protocols in use in Western countries 
The goal of ART therapy is to reduce morbidity and mortality related to HIV infection, and 
consequently improve the quality of life of the individual. The effectiveness of the regimen is 
assessed by the plasma virological suppression (within the first 3-6 months) and by the 
improvement of the immunological picture (recovery of CD4 lymphocytes). 
The therapy of the naive patient, that is not yet subjected to antiviral treatments, uses the 
combination of multiple drugs (first-line treatment). 
For example, in Italy there are 26 clinically available drugs. The choice of the appropriate 
combination goes from the evaluation of several factors: virological and immunological 
efficacy, toxicity and tolerability, cost effectiveness, possible interactions with other drugs, 
viral load value at the beginning of therapy, presence of possible resistance mutations 
specific clinical pictures and coinfections . 
 
Although in most cases the therapeutic regimens are effective and lasting over time, a non 
negligible percentage of patients can experience a therapeutic failure, and the decision to 
change the pharmacological regimes is conditioned by the reappearance of an appreciable 
viral load, defined as the overcoming stable threshold of 200 copies / mL (to discriminate from 
so-called viremic blip: isolated and transient peaks, not indicators of stable replication 
recovery). Furthermore, the analysis of resistance mutations is fundamental. 
The formulation of a new therapeutic formulation (called the second line) must take into 
account the recommendation to replace drugs that are no longer effective with drugs 
belonging to other classes, particularly in the presence of mutations that infuse drug cross-
resistance. 
 
1.12.2 Therapeutic schemes In Malawi  
 
The criteria to be taken into consideration for the therapeutic approach in the developing 
countries are significantly different from the international guidelines, affected in particular by a 
smaller variety of available drugs, lower health expenditure ceilings, different nutritional 
conditions and environmental issues, greater difficulty in adhering to therapies and follow-up 
cases. 
The free ART was rolled out in 2004 and since then patients starting ART are registered & 
followed up according to guidelines. 
By end of 2017, about 1.1 million were on PLHIV and 796 100 patients are alive and on ART. 
Since 2017, HIV positive patients were eligible to the antiretroviral treatment based on 
biological criteria as CD4 count and/or viral load, with some modification in these values 
threshold during the years 
All pregnant women are eligible for ART .Since 2013 the Center of Disease Control of Atlanta 
CDC supported in Malawi the Option B+. This approach offers all HIV-positive pregnant or 
breastfeeding women lifesaving antiretroviral treatment (ART) for their entire lives. Option B+ 
simplifies the ART regimen to one pill once a day making it much easier for the patient to take 
and far easier to implement. This option was spread in all the Africa Countries, and was used 
until the adoption of the universal ART eligibility for PLHIV ( test and treat approach), in 2016. 
The previous schemes, were: one, colled option A, provided just a single dose of nevirapine 
at the delivery, and the second colled option B, provided discontinuation of NVP based ART 
after delivery, These schemes may have played a role in development of drug resistance 
mutations. 
(144-146) 
 
The ART regimens in use at the moment are: 
-Regimen 1A (TDF 300/3TC 300/EFV 600) is the standard first line start regimen for all 
patients from 35kg  
-Regimen 2A (AZT 300/3TC 150/NVP 200) is the standard first line start regimen for all 
patients under 35kg 
- Regimen 3A (Reltagravir, Darunavir, ritonavir, abacavir 600+lamivudine 300) 
-A transition to dolutegravir (DTG) based regimens for eligible patient groups as 1A is 
planned for January 2019 
 
 
 
 
 
 
 
 
 
 
 
At the time of the study, the drugs available for conventional treatments consisted of a limited 
number of drugs, showed in the following table: 
 
Retrotrascrittasis 
inhibitors 
Nucleosidics 
NRTI 
Stavudine (d4T) 
Zidovudine (AZT) 
Lamivudine (3TC) 
Abacavir (ABC) 
Tenofovir (TDF) 
Non-Nucleosidics 
NNRTI 
Nevirapine (NVP) 
Efavirenz (EFV) 
Protease inhibitors PI 
Atazanavir (ATV+r) 
Lopinavir (LPV+r) 
 
The limitations in the possibilities of choice are evident, restricted to the drugs of the first 
generations, less expensive. In particular, Lamivudine is taken as a reference drug for all first-
line treatments, because it is well tolerable and able to express a residual function even on 
resistant viral populations. 
As a first-line treatment for adult patients above 35 kg weight the combination TDF, 3TC and 
EFV is recommended, while for children or adults below 35 kg the standard is AZT, 3TC and 
NVP (Tenofovir may have harmful effects on growing bones of children). 
Alternative combinations are considered in particular conditions and it is also indicated to 
provide for severe drug intolerance responses with replacement with other regimens, possibly 
without interruption. 
The possibility of incurring a therapeutic failure is monitored by the viremia dose, performed 
after 1 year from the start of therapy, and once a year in consecutive years. It is 
recommended to set up a second-line treatment if the viral load is higher than 1,000 copies / 
mL, or between 1000 and 4999 copies / mL for two successive repetitions, provided that in 
any case a satisfactory adherence to the treatments by the subjects in the months prior to the 
test. 
1.13 DRUG RESISTANCE HIV STUDY 
1.13.1.Resistance mutations 
We can classify mutations according to the family of drugs that cause the onset and to which 
they confer resistance. 
 
Mutations vs NRTI: 
The NAM complex (nucleoside analogue mutations (NAMs) called either thymidine analogue 
mutations (TAMs). It is a group of 6 mutations that tend to appear sequentially and 
cumulatively, giving total resistance to Zidovudine AZT and Stavudine d4T and partial 
resistance to other NRTIs excluding Lamivudine 3TC. They give the RT the ability to remove 
the nucleoside terminator by a phosphololysis reaction. It has been proved that these 
mutations appear to follow two distinct pathways with which mutations are associated, thus 
distinguishing between NAM-1 (M41L, L210W and T215Y / D) and NAM-2 (D67N, K70R, 
T215F / I and K219Q / E ). Once four or more of these mutations are present, the resistance 
is total. 
The M184V mutation, which appears to be the most frequent, makes HIV totally resistant to 
Lamivudine and Emtricitabine, but at the same time more sensitive to the action of AZT, d4T 
and TDF. It is expressed with an increase in viral transcription fidelity and therefore is 
associated with a decrease in the onset of new mutations and the synthesis rate of RT in 
general. 
The mutations of the 65-75 region (K65R, T69D / N, L74I / V, V75A / M / T) which confer 
resistance to ddC, ddI, TDF and d4T. 
The Q151M mutation, rarer but associated with a total Multi Drug Resistance (MDR) 
framework for all NRTIs. It appears to appear in association with other mutations such as 
NAM, insertions in 69, M184, V75, E44 or V118. 
 
Mutations vs NNRTI: 
Among the most frequent and able to confer cross-resistance to many of the drugs in this 
class, mutations in the 98-108 region (A98G, L100I, K101E, K103N, V106A, V108I). In 
particular, K103N confers absolute multiple resistance for NNRTIs. 
Mutations in the 181-190 region also tend to give cross-resistance. These are mutations 
Y181C / I, Y188L / C / H and G190A / S. 
The mutations in the 225-236 region (P225H, M230L, P236L) are more rare and give 
resistance only to one or two NNRTI drugs. 
 
Mutations vs PI: 
Primary mutations (D30N, G48V, I50V / L, V82A / T / F / S, I84V / A / C, L90M). Among these 
some confer complete resistance to only one or two drugs and partial to others (D30N for 
Nelfinavir, G48V for Saquinavir, I50V for Amprenavir, V82A for Ritonavir and Indinavir, L90M 
for Saquinavir and Nelfinavir), while I84V gives cross resistance towards all PI inhibitors 
except Lopinavir. 
The secondary (L24I, V32I, L33F, M46I / L, I47V, F53L, I54V / T / A / S / M / L, G73C / S / T / 
A, N88S / D) instead consolidate the resistances of the primary mutations or give new partial 
resistances. 
Various natural polymorphisms are also known to show a slight increase in the effects of 
previous mutations if they are present in combination (L10I, K20R, M36I, L63P, A71V, V77I). 
 
Mutations vs FI (Fusion Inhibitors): 
These drugs target the gp41 protein, so resistance mutations will be identified in the env 
region of the HIV genome. 
Several mutations in the 36-45 region are known that make the virus resistant to the effects of 
Enfurtivide (G36D / E / S, V38A / M / E, Q40H, N42T / D, N43D / K, L45M). 
 
Interaction with resistance pathways 
There appear to be associations between the new mutations and the NAM-1 and NAM-2 
pathways. 
In detail, mutations T39A, K43E / Q, K122E, E203K, and H208Y are for example associated 
with NAM-1 mutations. They are also located very close to the interaction site with the 
nucleotides to be incorporated, suggesting that they can contribute to mediate the effect of 
resistance to NRTIs. 
Instead the K20R and D218E mutations are significantly associated with the NAM-2 pattern. 
In particular, D218E seems to correlate with the use of Zidovudine, an observation in line with 
the results of another recent study demonstrating that prolonged exposure to Zidovudine 
would seem to correlate with an increase in the probability of observing the NAM-2 pathway. 
The co-presence of K43E, K122E, or H208Y alone or as a cluster with NAM-1 has been 
associated with higher viremia and fewer CD4 cells for therapeutic failure, and this fact may 
suggest a compensatory role for these mutations, which leads to improved viral replication. 
It is also conceivable that the class 1 and 2 mutations contribute to a further increase in the 
level of resistance. The phenotypic resistance data in the Stanford HIV Drug Resistance 
Database support this hypothesis. The presence, either individual or combined, of K43E, 
K122E, and H208Y with and without NAM-1 has been associated with a high increase in 
zidovudine resistance. 
It has recently been shown that the H208Y mutation, frequently selected in combination with 
the NAM pathway under combined therapy with zidovudine and lamivudine, is associated with 
an increase in the level of resistance to zidovudine (147). 
 
Polymorphisms 
single nucleotide polymorphism (SNP) is a genetic polymorphism between two genomes that 
is based on deletion, insertion, or exchange of a single nucleotide. 
genetic polymorphism is the occurrence, together in the same population, of two or more 
genetically determined phenotypes. 
 
Special features of subtype C 
 
For many years now it has begun to understand how the different viral subtypes have 
differences not only at the epidemiological level, but also at the clinical level, in particular in 
the acquisition of resistance mutations and differences in the pathways. 
For example, some strains of subtype C spontaneously present the G190A polymorphism, 
thus becoming naturally resistant to some NNRTIs (Efavirenz and Nevirapine). 
Even synonymous mutations may be significant, in the C strains, the V106M mutation is 
common in subjects treated with Efavirenz. Clinical relapse is important because V106M 
confers cross-resistance to the entire NNRTI class. 
 
In recent years we are witnessing the growth of a substantial body of studies concerning the 
characteristics of the subtype C, especially by the countries most involved in the issue, such 
as South Africa and India. 
Another case concerns the high frequency of occurrence of nevirapine resistance mutations 
following the administration of a single dose of nevirapine in women to prevent mother-child 
transmission of HIV (148,149). These studies have found the high resistance rate found in 
African women at the sixth to eighth week after the administration of nevirapine, over 40% (in 
some cases, as for Malawi, almost 70%), if the rate of mutation is significantly lower in the 
other genotypes, around 20%. 
Repeated studies in recent years have led to some interesting conclusions: the natural 
polymorphisms present in subtype C in codons 64, 65 and 66 of RT could play an important 
role in the acquisition of resistance against tenofovir disoproxil-fumarate (TDF) (150, 151) 
Indeed, the characteristic adverse mutation to this nucleoside analogue is K65R; therefore, 
the polymorphisms close to that codon could potentially be attributed to the high rate of 
resistance development observed in sub-Saharan regions, where TDF is one of the standards 
of therapeutic strategies. 
 
The work of White E. et al (152) solved the dilemma by demonstrating that by analyzing the 
data, an apparent risk of developing TDF resistance more than twice on the part of the C 
subtype compared to subtype B was observed. However, stratifying the data for the clinical 
condition -demographic of the subjects to the study, the differences between the two groups 
vanish. By adjusting the data in this way, the confounding factors such as adherence, viral 
load baseline and tightness of resistance monitoring, apparently constituted a bias against the 
studies comparing two different cohorts: subjects affected by subtype C in countries in 
development and subjects with subtype B in countries with better health standards. 
 
There are three main categories of HIV drug resistance (HIVDR):  
1. Acquired HIV drug resistance (ADR) develops when HIV mutations emerge due to viral 
replication in individuals receiving ARV drugs. 
2. Transmitted HIV drug resistance (TDR) is detected in ARV drug-naive people with no 
history of ARV drug exposure. TDR occurs when previously uninfected individuals are 
infected with virus that has drug resistance mutations. 
3. Pretreatment HIV drug resistance (PDR) is detected in ARV drug-naive people initiating 
ART or people with prior ARV drug exposure initiating or reinitiating first-line ART. PDR is 
either transmitted or acquired drug resistance, or both. PDR may have been transmitted at 
the time of infection (i.e. TDR), or it may be acquired by virtue of prior ARV drug exposure 
(e.g. in women exposed to ARV drugs for the prevention of mother-to-child transmission of 
HIV, in people who have received pre-exposure prophylaxis, or in individuals reinitiating first-
line ART after a period of treatment interruption without documented virological failure). ARV 
drug-naive applies to people with no history of ARV drug exposure. 
 
1.13.2. Relevance of Transmitted Drug Resistance mutations  study (TDR) .. 
Although all the 3 categories are a public health concern as for example transmitted 
resistance has the potential to more rapidly reverse the effectiveness of first-line antiretroviral 
therapy at the population level. Persons with transmitted drug resistance begin antiretroviral 
therapy with a lower genetic barrier to resistance, a higher risk of virologic failure, and a 
higher risk of developing resistance even to those drugs in their regimen that were originally 
fully active. Surveillance of transmitted resistance can supply programmatic information in 
designing education and prevention programs as well as supporting a wise use of 
antiretroviral drugs by clinicians and policy makers. 
Of the 26 countries with national HIVDR surveys that are completed or ongoing, 14 have 
reported data to WHO (fig.6) (153) 
 
 figure 6 .. implementation of WHO pretreatment resistance surveys 2014-2017   
Levels of pretreatment resistance to efavirenz or nevirapine, the most affordable and widely 
used drugs in first-line ART, reached 10% or above in six out of 11 countries that reported 
PDR survey data. 
 
Population-based HIV Impact Assessment surveys in Malawi.  
 
The frequency of drug resistance mutations among incident HIV infections Population-based 
HIV Impact Assessment (PHIA) surveys are used to estimate the national incidence of HIV 
among adults (15–59 years), and the national prevalence of viral load suppression (HIV 
RNA<1.000 copies/ml). Unfortunately the size of the sample is very reduced (n=26)-  (report 
who 2107) 
In Malawi there are no laboratories equipped for the study of viral resistance, and the samples 
for epidemiological surveillance are sent abroad with the support of the CDC (Atlanta) 
From a clinical point of view, the test is not used for pre-ART evaluation (antiretroviral 
therapy), nor for the transition from the first to the second therapeutic line (for which the viral 
load results are required). The clinical resistance test begins to be required for the transition 
from the second to a possible third line with integrase inhibitors that are starting to be 
available, but with much difficulty 
 
Anyway, the annual HIV incidence among 15-49 year-olds in Malawi’s PHIA survey was 
0.32% (95% CI 0.16–0.48). Among those specimens (n=26) classified as recently infected, 
and with genotype data available, DRMs were detected in four out of 26 specimens. One 
sequence had high-level EFV/NVP resistance with K103R/S; two had low-level resistance to 
EFV and intermediate to NVP with A98G; and a fourth had multiple mutations impacting both 
NRTIs and NNRTIs (A62V, K65N, D67I, A98G, K103NE, Y181C, G190A and H221Y 
The prevalence of HIVDR observed among recently infected people in Malawi is broadly 
consistent with the prevalence of HIVDR observed in the PDR surveys in the African Region. 
As mentioned above, the overall prevalence of viral load suppression among adults reporting 
current ART was nearly 90% (153) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim of the thesis 
 
Main objective 
The study general objective was the assessment of primary mutations in treatment-naïve HIV-
1 Subtype C-infected patients in Blantyre, Balaka, Machinga and Mangochi districts in Malawi 
identifying major transmitted drug resistant mutation frequency (TDR). 
 
Related objectives 
 
Determine primary mutations, accessory mutations and polymorphisms from 
resistance data of HIV-1 Subtype C infected patients in Malawi 
 
Explore any association between polymorphisms and accessory mutations with 
primary resistant mutations in HIV-1 Subtype C that could lead to mutational pathways 
and compare the observed mutational pathways in Subtype C with published 
mutational pathways in Subtype B 
 
Evaluate a cost effective In-House Plasma Method for HIV-1 Drug Resistance 
Genotyping  
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
 
First step 
In this laboratory-based retrospective study, we analyzed HIV sequences from 109 naive 
patients enrolled in the DREAM Program prior to treatment initiation between 2013 and 2015. 
This cohort did not have prior exposure to ARVs.  
Eligible patients responded to the following characteristics: 
- documented positivity for HIV 
- age over 15 years 
- ability to understand and accept informed consent 
- patients belonging to the DREAM program from Blantyre, Balaka, Machinga and Mangochi 
districts  
- availability of a plasma aliquot of at minimum 1 ml 
 
The DREAM program offers free of charge state-of-the-art treatment, following National 
guidelines, and laboratory monitoring (including viral load and CD4 counts, basic 
biochemistry, and complete blood counts) was done on a routine basis for all patients. 
 
For Viral Load determination, EDTA blood samples were collected and received at the 
laboratory within 4 hours of collection, immediately separated by centrifugation.  Two aliquots 
of plasma from each sample were prepared and stored at −80◦ for a minimum of one day and 
a maximum of 3 months. One aliquot was used for routine determination with the Abbott 
m2000 system and the second processed for genotyping. The HIV-1 RNA quantification was 
performed with the Abbott Real-Time HIV-1 assay (m2000rt; Abbott Molecular Diagnostics, 
Mississauga, Ontario, Canada) according to the manufacturer’s instructions. Purified RNA 
was obtained from a 0.6 mL plasma sample by using the m2000sp automated extractor, and 
qRT-PCR amplification and detection were done using the fully automated m2000rt 
instrument. 
 
Viral sequences of the pol gene were obtained from plasma (HIV-RNA) using the Trugene 
assay (Siemens Diagnostics) after extraction from whole blood (QIAamp DNA Blood Mini Kit, 
Qiagen, Hilden, Germany). This assay is a Sanger sequencing method that uses labeled 
fluorescent primers instead of labeled terminators. 
 
The assay consists of several processes: 
 Reverse Transcription and PCR Amplification: Reverse transcription of target RNA to 
generate cDNA using Reverse Transcriptase (RT) and PCR amplification of target 
cDNA using HIV-1 subtype B specific primers; 
 CLIP Reaction: CLIP sequencing of the PCR amplicons using HIV-l subtype B specific 
primers; 
 Gel Preparation, Polymerization, and Electrophoresis of CLIP Reaction Products:  
Separation of the CLIP sequencing reactions by electrophoresis on a polyacrylamide 
gel, and detection by laser-induced fluorescence; and 
 Data Analysis - Genotyping: Analysis of the forward and reverse CLIP sequences 
using the OpenGene system software. The end result is a TRUGENE HIV-1 
Resistance Report. 
All the tests were performed in the Blantyre DREAM laboratory. 
Among the 109 specimens, 61 were from females patients and 48 from males. 
 
Second step 
In a second step, we considered a second group of 425 sequences from a cohort of both 
naive and experienced patients (patients awaiting ART treatment or already undergoing 
therapy), to study different mutational pathways related to polymorphisms. 
Eligible patients responded to the following characteristics: 
- documented positivity for HIV 
- age over 15 years 
- ability to understand and accept informed consent  
- patients belonging to the DREAM project with a detectable viremia of> 1000 copies / mL  
- availability of a plasma aliquot corresponding to the sample tested for viremia 
 
The samples were all subjected to sequence analysis in the pro-pol region of the viral 
genome. 
For each sample, the whole obtained sequence was analyzed, and the information 
corresponding to the amino acid sequence of the over 1000 codons was analyzed and 
elaborated to highlight the positive and negative associations between the different groups of 
mutations. 
The polymorphisms were included in the study on the basis of their absolute frequency in the 
sample cohort: all the polymorphisms with a prevalence greater than 5% were considered, a 
level sufficient to guarantee a consistent statistical significance. 
 
Statistic analysis 
 
The data were analyzed using SPP software package version 20.0 (Chicago, IL) 
 
Optimization of the homemade method 
The optimization constitutes a series of processes and activities that ensured that the method 
was working in our laboratory. It included evaluating technical steps of the method and 
logistics, because in this method we have only one step that had to be done externally 
(sequence reaction reading), because there is no sequencer instrument in the country. 
 Technically, we found all the steps feasible from purification of RNA from plasma to 
amplification and sequencing. 
 Logistically, we identified a laboratory in South Africa, (Ingaba Biotechnical Industries) 
to read our sequences. Since we are exporting amplification products, this did not pose 
any documentation and declaration challenges. We got our read sequences from the 
reference lab within a week, and did not affect our overall turnaround time (TAT) of 
having resistance results within two weeks. 
 
DREAM - Home Made Method of HIV Drug Resistance Testing 
DREAM has been performing drug resistance testing in Malawi since 2008 using TRUGENE 
genotyping kit (Siemens Healthcare Diagnostics). The test was used for routine patient 
management and studies. This method was phased out in 2015. Through partnership with the 
University of Siena, DREAM implemented a homemade method of genotyping in 2016. The 
motivation behind the development of the new method arose from lack of in-country capacity 
for genotyping services and  the need of genotyping services in the country for patient care 
and studies having an ART program for over 14 years. In addition, the Country needs for a 
cost effective method of genotyping. The current basic commercial method like Abbott 
ViroSeq costs over $200 per patient. The DREAM homemade method costs under $95 and is 
suitable for limited resource countries. Developing this method was possible in our laboratory 
taking advantage of a lots of technical knowledges after having worked on the commercial 
method (TRUGENE sequencing procedure) for over 8 years (2008-2015).  
After providing informed consent, EDTA blood samples are collected and 2 aliquots of plasma 
from each sample are prepared and stored at -80⁰C. One aliquot is used for routine RNA 
quantification and the second one is genotyped for participants eligible for the study. 
The RNA quantification is done with the Abbott Real-Time HIV-1 assay (m2000rt: Abbott 
Molecular Diagnostics, Mississauga, Ontario, Canada) according to the manufacturer’s 
instructions. For HIVDR genotyping, viral nucleic acids are extracted from plasma specimens 
with QIAamp®Viral RNA kit (Hidden, Germany) according to manufacturer’s instructions.  
HIVDR genotyping of the protease (PR) and reverse transcriptase (RT) regions of HIV-1 pol 
gene are obtained using homemade method.  
Reverse transcription-polymerase chain reaction (RT-PCR) 
Briefly, the entire PR and amino acids 1-250 of RT is amplified using reverse transcription 
(random primer Promega Corporation 2800 Woods Hollow Road Madison, WI 53711 USA) 
Following RNA extraction, the RT-PCR was performed immediately: Add 20 µL of the viral 
RNA to 0.2 mL reaction tubes which were then placed into a thermal cycler(Geneamp PCR 
System 9700, Applied Biosystems) to relax the RNA secondary structure programmed at 70 
°C x 5 minutes. 
The master mix for 1° PCR was prepared with: 5 μl ImProm-II 5X Reaction Buffer (ref#: 
M289C, Promega, at -30°C), 1.8 μl MgCl2 (25mM, ref#: A351H, Promega, at -30°C)  4 μl of 
dNTP mix (1.25mM, Promega, at -30°C), 1.0 μl random primer ( 500µg/mL, ref#: C118A, 
Promega, at -30°C), 0.5 μl RNasin® ribonuclease Inhibitor (40U/µL, ref#: N211B, Promega, at 
-30°C) and 1 μl ImProm-II™ Reverse Transcriptase, (ref#: M314C, Promega, at -30°C) 
making a final volume of 30 μl. Following the denaturation of extracted RNA in the 
thermocycler, 14 μl of the master mix was added to each tube and run at the following PCR 
conditions: 
N° cycles   
1 25°C x 5 min 
1 37°C x 45 min 
1 80°C x 5 min 
 
The RT-PCR product (cDNA) was stored at 2-8°C in the refrigerator pending nested PCR 
Nested PCR 
The nested PCR is performed with primers 533 and 534 (nPCR1) and primers 535 and 536 
(nPCR2) as showed in tab 1 using Go Taq® G2 Hot start polymerase kit (Promega 
Corporation, 2800 Woods Hollow Road Madison, WI 53711-5399 USA).  
 
Primer Direction Sequence (5’.........>3’) Location 
on HXB2 
Purpose 
P533 antisense GCTAYTAARTCTTTTGWTGGGTCATA 3504-
3519 
1° PCR 
P534 Sense AAAARGGYTGTTGGAAATGTGG 2018-
2039 
1° PCR 
P535 Sense GARAGRCAGGCTAATTTTTTGGGA 2071-
2095 
2° PCR 
P536 antisense TCTTTTARAATYTCCCTGTTYTCTGC 3459-
3484 
2° PCR 
P213 Sense GCTTTTATTTTTTCTTCTGTCAATGGCCA 2619-
2647 
Sequencing 
P219 antisense TTTCCAATTAGTCCTATTGARACTGTRCC 2547-
2575 
Sequencing 
P535 Sense GARAGRCAGGCTAATTTTTTGGGA 2071-
2095 
Sequencing 
P536 Antisense TCTTTTARAATYTCCCTGTTYTCTGC 3459-
3484 
Sequencing 
 
tab. 1 sequence of primers used in nested PCR 
The master mix for1° PCR  was prepared with: 10 μl 5X Colourless Go Taq Flexi Buffer (ref#: 
M890A, Promega, at -30°C), 5 μl MgCl2 (25mM, ref#: A351H, Promega, at -30°C)  3.2 μl of 
dNTP mix (1.25mM, Promega, at -30°C), 0.3 μl primer 533 , 0.3 μl primer 534, 0.2 μl Go 
Taq® G2 Hot Start Polymerase (5U/µL ref#: M7408, Promega at -30°C), 26 μl Nuclease free 
water (ref#: 1039498,QIAGEN at 15-25°C, making a final volume of 50 μl. Then 45 µL of the 
1° PCR master mix was distributed into each 0.2 mL reaction tubes to which 5 µL of template 
cDNA was added. The samples were run in a thermocycler programmed at: 
N° cycles Denaturation Annealing Extension 
1 94°C x 4 min   
5 95°C x 40 sec 56°C x 30 sec 68°C x 1 min 45 sec 
25 95°C x 40 sec 54°C x 30 sec 68°C x 1 min 45 sec 
1   54°C x 1 min 
   68°C x 8 min 
 
The DNA was stored at 4 °C pending 2° PCR 
The master mix for2° PCR  was prepared with: 6 μl 5X Green Go Taq Flexi Buffer (ref#: 
M891A, Promega, at -30°C), 3 μl MgCl2 (25mM, ref#: A351H, Promega, at -30°C)  0.8 μl of 
dNTP mix (1.25mM, Promega, at -30°C), 0.3 μl primer 535 , 0.3 μl primer 536, 0.2 μl Go 
Taq® G2 Hot Start Polymerase (5U/µL ref#: M7408, Promega at -30°C), 17.4 μl Nuclease 
free water (ref#: 1039498,QIAGEN at 15-25°C, making a final volume of 28.4 μl. Then 28 µL 
of the 2° PCR master mix was distributed into each 0.2 mL reaction tubes to which 2 µL of 
DNA template was added. The samples were run in a thermocycler programmed at: 
N° cycles Denaturation Annealing Extension 
1 94°C x 4 min     
5 95°C x 40 sec 56°C x 30 sec 68°C x 1 min 45 sec 
29 95°C x 40 sec 54°C x 30 sec 68°C x 1 min 45 sec 
1     54°C x 1 min  
      68°C x 8 min  
 
The DNA was stored at -20 °C pending confirmation of amplification PCR products by 
agarose gel electrophoresis. 
 
Detection of PCR products on agarose gel 
The confirmation of PCR amplification results was obtained by electrophoretic run on 1.5% 
agarose gel. During the preparation 10 μl of Atlas Clear DNA Stain (cat# BH40501, 
BIOATLAS, at 4°C) was incorporated, and was intercalated between the bases of the nucleic 
acid and allowed the visualization of the DNA under UV exposure. Moreover, it was possible 
to recognize the presence and size of the amplification product by a molecular ladder loaded 
simultaneously with the samples (marker 100, BenchTop 100bp DNA ladder, Ref: G210A, 
Promega corporation USA). The expected PCR product that was required for sequencing 
measured 1.08kb and fell just below the 1.2kb marker 
PCR purification 
The PCR products were purified using EXOSAP-IT Purification Kit (Affymetrix, Santa Clara, 
California, USA) 2uL of ExoSAP-IT was aliquoted for 5uL of PCR product, vortexed, spin and 
run in the thermocycler on the following program:  
 
 
N° cycles   
1 37°C x 15 min 
1 80°C x 15 min 
 
Cycle sequencing 
The purified PCR product was directly sequenced in both directions using BigDye™ 
Terminator Cycle Sequencing Ready Reaction Kit version 3.1 (Applied Biosystems, Foster 
City, CA, USA). The master mix for sequencing reaction for each primer was prepared with: 
3.2 μl primer (1pmol/ uL), 2.3 μl Nuclease free water (ref#: 1039498, QIAGEN), 1 μl of BigDye 
buffer (5X), 0.5 μl of BigDye terminator mix, making a final volume of 10 μl. Then 7 µL of the 
cycle sequencing master mix was distributed into appropriate wells of a 96-well reaction plate 
to which 3 µL of purified template DNA was added. The samples were run in a thermocycler 
programmed at: 
N° cycles Denaturation Annealing Extension 
1 96°C x 1 min     
25 96°C x 10 sec 50°C x 5 sec 60°C x 4 min  
The sequencing PCR products were stored at -20 °C pending sequencing purification. 
Sequencing purification 
Sequencing purification was done with BigDye® XTerminator™ Purification Kit (20 mL 
product code 437487, Life Technologies) to remove dye terminators. The procedure involved: 
Aliquot 10uL to each well in the PCR reaction plate with sequencing PCR products, followed 
by dispensation of 45uL of SAM solution to each well. The sealed reaction plate was vortexed 
for 30 min at 2000rpm and spun for 3 min at 3000rpm. A new seal was then applied and the 
plate was run in a sequencer to generate sequence reads. 
Sequence Detection 
Sequence reads were done externally at Ingaba Biotechnical Industries, In Pretoria, South 
Africa. The shipment was by FedEx courier. 
 
 
Sequence Analysis and Interpretation 
DNAStar Lasergene was used to edit sequences and generate consensus sequences 
before analysis.  
Sequence traces are aligned and consensus sequence constructed using Seqman Pro 
software (Madison, Wisconsin, USA). 
Interpretation of results was done with International Antiviral Society-USA list-2016 and 
Stanford HIV Drug Resistance Database. (www.stanford.org)  
 
Quality Assurance 
In-house positive and negative controls were prepared and included in each RT-PCR reaction 
run exactly as testing specimens to check the validity of the run. Negative control was (HIV 
negative) human plasma stored at -80°C. The positive control was normal human plasma 
spiked with a plasmid PLN4P12, stored at -80°C. The run was valid when there was no visible 
band in the negative control and the positive control showed amplification and visible correct 
sized band (1.06kb) during gel electrophoresis. The test was registered in the external quality 
assessment scheme with a United Kingdom based Quality for Molecular Diagnostics 
(QCMD). 
 
General characteristics of the method 
The homemade method was optimized and validated on plasma specimens. The Abbott 
m2000sp extractor was found to be equally effective in producing quality nucleic acids for 
sequencing. It can detect group M & O It has sensitivity for VL>1000 copies 
The Ingaba Biotechnical Industries (Pty) Ltd in Pretoria, South Africa was identified to read 
the sequences at a cost of $3.41 per unit. The overall total cost per test was $95. Turnaround 
time of receiving sequence data was 7 days.  Seqman Pro 14 Software, was selected owing 
to its cost effectiveness and I got trained on how to use it at Milano Sacco  
Validation of the method 
The objective was to validate DREAM homemade method as one of cost effective methods 
for HIV genotyping using plasma samples. 
The validation includes establishment of analytical performance characteristics such as 
sensitivity, specificity, precision, reproducibility and accuracy: 
 Amplification sensitivity was evaluated on HIV-1 positive plasma samples (n50)  with 
known viral loads ranging from about 1000 to 5.8 million RNA copies/mL 
 Amplification specificity was evaluated on molecularly confirmed HIV-1 negative 
samples (n10) 
 The precision and reproducibility were carried out on 3 samples with 5 replicates (n15) 
representing varying viral loads (low VL about 1000, medium VL about 10 000, high VL 
about 150 000 copies/mL) 
 Accuracy is planned to be assessed by comparing paired sequences (n10) generated 
by DREAM homemade method and the method used by CDC as a gold standard. 
 Another way of checking accuracy was to get registered to an external quality 
assurance scheme, which we did with Quality Control for Molecular Diagnostics 
(QCMD), a London based provider. 
The method showed: 
 100% sensitivity on samples with HIV-1 viral load >1000 copies/mL 
 100% specificity on HIV-1 negative samples 
 precision and reproducibility data showed high nucleotide sequence identities, 
>99.79+/-0.10, and 99.75+/-0.10 respectively 
 
 
RESULTS 
 
1.0 Frequency of Transmitted Drug Resistance in HIV Naïve patients 
 
The study objective, as we said, was to describe the frequencies of major HIV-1 drug 
resistance associated mutations (RAM) and those listed for surveillance of transmitted drug 
resistance (TDR) in a cohort of drug-naïve patients. 
 
Specifically, we calculated the proportion of subjects with transmitted drug resistance 
mutations TDR, and the proportion of subjects with NRTI-TDR, NNRTI-TDR, PI-TDR. 
 
In this laboratory-based retrospective study, we analyzed HIV sequences from 109 patients 
enrolled in the DREAM Program prior to treatment initiation between 2013 and 2015. This 
cohort did not have prior exposure to ARVs. The HIV drug resistance genotyping was 
performed at Blantyre DREAM Laboratory. 
 
Among the 109 specimens, 61 were from females patients and 48 from males. 
The baseline characteristics are shown in the table 1 below and the results of baseline 
characteristics for the population are reflecting the common Malawian HIV infected patients. 
 
Variables at baseline  
Observation time 2013-2015 
Gender Female (61), male (48), total 109 
Age (years) 33 (IQ:26-41) 
CD4 count (cell/mm
3
) 554 (IQ:385-728) 
HIV Viral Load (Log
10
 copies/mL) 3.97 (IQ:3.39-4.43) 
Haemoglobin (g/dL) 11.30 (IQ:10.00-12.65) 
Body Mass Index(Kg/m
2
) 21.95 (IQ:18.86-26.17) 
 
Table 1: patient characteristics 
 Out of 109 patients, 40 (36,70%) presented at least one TDR-associated mutation  as shown 
in table 2 
 
Resistance mutation Abs frequency (n:109) % frequency 
TDR 40 36,70 
NRTI-TDR 13 11,93 
NNRTI-TDR 32 29,36 
NRTI & NNRTI 5 4,58 
 
Table 2: Transmitted Drug Resistance mutation frequency 
 
1.1 Frequency of nucleotide reverse transcriptase inhibitors (NRTIs) resistance 
mutations in naïve patients 
 
The observed frequency of nucleoside reverse transcriptase inhibitors (NRTIs) resistance 
mutations was M184V (4.58%), K70R/E (3,67%), D67N (2,75%) and  T69D (1,83%) 
 
Table 3: frequency of NRTIs mutations in naïve patients 
 
NRTI resistance mutation Frequency (N) 
M184V 4,58% (5/109) 
K70R/E/T 3,67% (4/109) 
D67N/G 2,75% (3/109) 
T69D/N 1,83% (2/109) 
K219Q/E 0,92% (1/109) 
 
 
M184V causes high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI 
and ABC. However, it increases susceptibility to AZT and TDF. 
K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly 
d4T (stavudine, nucelosidic analogue). 
D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. 
When present with other TAMs, it contributes to reduced susceptibility to ABC, ddI, and TDF. 
T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T. 
K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, 
ABC and TDF. 
 
1.2 Frequency of non-nucleotide reverse transcriptase inhibitors (NNRTIs) resistance 
mutations in naïve patients. 
 
The prevalence of TDR to non-nucleoside reverse transcriptase inhibitor (NNRTI) was 
K103N/S (11,93%), G190A (6.42%), Y181C/V (3,67%), V106M (2,75%), K101E (3,67%), 
V179D/T (4,59%) and E138K/Q/R/G/A/S (6.42%). 
Other observed NNRTI mutations were observed at a frequency of <5%. 
 
 
NNRTI resistance mutation Frequency (N) 
K103H/N/S/T 11,93% (13/109) 
E138K/Q/R/G/A/S 6,42% (7/109) 
V179D/T 4,59% (5/109) 
K101H/E/P/Q 3,67% (4/109) 
Y181C/V 3,67% (4/109) 
G190A/S 6,42% (7/109) 
V106M/A 2,75% (3/109) 
M230I/L 1,83% (2/109) 
 
 
 
K103N indicates resistance to efavirenz (EFV) and nevirapine  (NVP). The presence of  
11.93% of this mutation in naïve patients is worrying because in the programmatic 
antiretroviral program being implemented in Malawi, 93% of patients are on first line regimen 
that contains TDF/3TC/EFV (5A).and the rest are on 2A regimen (AZT/3TC/NVP). 
 K103N is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. 
K103S is a non-polymorphic mutation that causes high-level resistance to NVP and 
intermediate resistance to EFV. Because K103S is a 2-bp change from the wildtype K and a 
1-bp change from K103N, patients with K103S may be likely to have once had K103N. 
Y181C indicates possible resistance to EFV and the presence of this mutation may indicate 
undetected presence of other NNRTI resistance associated mutations. 
G190 A/S  is a nonpolymorphic mutation selected by NVP and EFV. Alone G190A reduces 
NVP susceptibility >50-fold and EFV susceptibility 5 to 10-fold. 
V106M is a nonpolymorphic mutation selected primarily by EFV and NVP. It is particularly 
common in subtype C viruses. It causes >30-fold reduced susceptibility to NVP and EFV 
. K101E usually occurs in combination with other NNRTI-resistance mutations. Alone it 
reduces susceptibility to NVP by 3 to 10-fold, to EFV by 1 to 5-fold. K101H is a 
nonpolymorphic mutation selected in patients receiving NVP, EFV, and ETR. When it occurs 
in combination with other NNRTI-resistance mutations, K101H is associated with reduced 
susceptibility to NVP and EFV. K101P is a nonpolymorphic two base-pair mutation selected in 
persons receiving each of the NNRTIs except possibly DOR for which few data are available. 
It reduces NVP, EFV, and RPV susceptibility by >50-fold. K101Q is a minimally polymorphic 
accessory mutation weakly selected in patients receiving NVP and EFV. It appears to have 
minimal, if any, detectable effect on NNRTI susceptibility 
 
There were 5 specimens (4,58%) that had both NRTI and NNRTI resistance. 
 
Frequency of  resistances to some specific drugs as zidovudice, lamivudine, tenofovir , 
nevirapine are shown in table 5. 
Resistance frequency to AZT is 5,5 % (6/109) while the frequency of resistance against 
Lamivudine 3TC is 4,6% (5/109). The frequency for Tenofovir TDF is low and is value is 
around 1,8% (2/109) while we detected a very high percentage for frequency of resistance 
against NVP/EFV ; 27,5% of naïve subjects shown a resistance against these drugs  
(30/109). 
 
 
  
 
 
 
 
 
Res_AZT 
 Frequenc
y 
Percent Valid 
Percent 
Cumulative Percent 
Valid 
Absent 103 94.5 94.5 94.5 
Present 6 5.5 5.5 100.0 
Total 109 100.0 100.0  
Res_3TC 
 Frequenc
y 
Percent Valid 
Percent 
Cumulative Percent 
Valid 
Absent 104 95.4 95.4 95.4 
Present 5 4.6 4.6 100.0 
Total 109 100.0 100.0  
Res_TDF 
 Frequenc
y 
Percent Valid 
Percent 
Cumulative Percent 
Valid 
Absent 107 98.2 98.2 98.2 
Present 2 1.8 1.8 100.0 
Total 109 100.0 100.0  
Res_NVP_EFV 
 Frequenc
y 
Percent Valid 
Percent 
Cumulative Percent 
Valid 
Absent 79 72.5 72.5 72.5 
Present 30 27.5 27.5 100.0 
Total 109 100.0 100.0  
 
Table 5: resistance frequencies to some specific drugs 
 
With the  prevalence of this mutation in about a quarter of the HIV positive naïve population , 
the initiated ART will not maximally suppress the viral replication. 
 
 
 
 
 
 
 
 
2.0 Frequencies of resistance mutations and polymorphisms 
 
The 425 specimens were studied by stratifying them into 4 subgroups for each association: 
- who presented a given resistance mutation and a given polymorphism, 
- who only had the mutation, 
- who only the polymorphism, 
- who none of the two. 
 
This is to test every possible mutation / polymorphism association between the genetic 
variants included in the study. 
For each pair of data, the statistical significance of the difference in the relative frequencies in 
the 4 subgroups was calculated using a statistical method (two-frequency test), in order to 
highlight any positive or negative correlations between polymorphisms and  known resistance 
mutations. Only the correlations that showed a high degree of significance were considered. 
Resistance mutations were subdivided into some groups: mutations of the NAM-1 and NAM-2 
pathways, the M184V mutation, the other resistances against NRTIs and those against 
NNRTIs. Mutations for Protease Inhibitors (PIs) that emerged from sequencing  are also 
reported, although they have not been considered for association studies in this work. 
 
2.1 Frequency of polymorphisms 
 
Of the 216 codons subjected to nucleotide variations found through all the sequencing 
products in the RT region, the most represented ones were selected to ensure greater 
statistical significance, reducing the number to 22 codons. 
Polymorphisms at frequencies greater than 10% were included in the study, with the 
exception of the K43E / D mutation, for which a previous study had shown interesting results 
and, despite being present in less than 10% of the sequences, was found with an acceptable 
frequency . 
 
 
 
 
 ABSOLUTE FREQUENCIES 
(n=425) 
PERCENTAGE 
FREQUENCIES % 
T39E/D 345 81.18 
E40A/D/H 62 14.59 
K43/E/D 20 4.71 
S48/T/Q 346 81.41 
V60I/V 106 24.94 
E122K/G/P 85 20.00 
D123S/G 272 64.00 
I135T/M 133 31.29 
S162Y/D/H 97 22.82 
K166R/E 49 11.53 
K173T/A/D 389 91.53 
Q174K/R 234 55.06 
D177E/K/G 314 73.88 
I178L/M 130 30.59 
G196R/M/E 64 15.06 
T200A 406 95.53 
I202I/V/M 44 10.35 
Q207E/D 393 92.47 
R211K 303 71.29 
L214F 331 77.88 
L228R 50 11.76 
V245Q/T/E 359 84.47 
 
Many of these polymorphisms were found to be present in very high percentages, making it 
part of the consensus sequence for the subtype C. They were however included in the study 
to investigate the existence of any natural predispositions related to those codons. 
Many of the mutations taken into consideration from the previous work and found to be 
involved in significant associations with resistance mutations, were found in very low 
percentages in the HIV subtype C samples, so that they could not be considered statistically 
significant and excluded from the elaborations. However, these differences are equally 
important, because they suggest that the different subtypes could use different mutational 
pathways during the  acquisition of the resistance. 
 
 
2.2 Associations between polymorphisms and resistance mutations 
 
To test the statistical significance of all possible associations, the sample cohort was divided 
between those who tested positive for a new mutation or polymorphism, and those who did 
not present the new mutation or polymorphism. The incidence frequencies of the various 
resistance mutations in the two separate groups were then calculated to determine the 
presence and strength of the associations. 
We have thus identified positive associations, that is, the presence of the new mutation or 
polymorphism is accompanied by a greater frequency of resistance mutations; and negative 
associations, in which the presence of polymorphism is linked to a lower frequency of 
resistance mutations, suggesting the possibility that the two types of mutation may be to 
some extent mutually excludable. 
The following tables show all the associations founded and subdivided by the various groups 
of resistance mutations defined previously. 
 
 
NAM-1 
 Positive associations negative associations 
M41L V60I 
I178L/M 
L214F 
L228R 
V245Q 
P<0,001 
P<0,05 
P<0,05 
P<0,05 
P<0,05 
S48T/Q P<0,05 
L210W V60I 
G196R/M/E 
L228R 
P<0,05 
P<0,05 
P<0,01 
S48T/Q P<0,001 
T215Y V60I P<0,05   
 
 
The association of V60I with all three mutations of the NAM-1 pathway, the (positive) 
association of L228R and (negative) of S48T/Q with M41L and L210W are very significant. 
 
 
 
 
 
 
 
NAM-2 
 Positive associations negative associations 
D67N/G V60I 
L228R 
P<0,001 
P<0,01 
S48T/Q 
K173T 
P<0,001 
P<0,005 
K70R/E/T V60I 
I135T/M 
I178L/M 
L228R 
P<0,05 
P<0,01 
P<0,05 
P<0,001 
S48T/Q 
K173T 
V245Q 
P<0,001 
P<0,005 
P<0,05 
T215F/I L228R P<0,01 S48T/Q P<0,01 
K219Q/E I135T/M 
L228R 
P<0,05 
P<0,001 
S48T/Q 
K173T 
L214K 
P<0,001 
P<0,01 
P<0,001 
 
 
Very significant associations are found between the L228R and all 4 mutations of the NAM-2 
pathway, and the associations of V60I and I135T/M with two mutations each. The negative 
associations with S48T/Q and K173T are also very evident. 
 
 
 
M184V (Lamivudine) 
 Positive associations negative associations 
M184V I135T/M 
L228R 
P<0,001 
P<0,05 
S48T/Q 
K166R/E 
L214F 
V245Q 
P<0,05 
P<0,05 
P<0,05 
P<0,001 
 
 
 
 
The most significant associations are those with I135T/M (positive) and with V245Q 
(negative). 
 
 
 
Other NRTI 
 Positive associations negative associations 
E44D V60I 
K166R/E 
P<0,05 
P<0,005 
S48T/Q P<0,01 
A62V I135T/M 
R211T/S 
P<0,05 
P<0,001 
R211K P<0,05 
K65R Q174K 
I202V/M 
P<0,05 
P<0,05 
V60I/V P<0,05 
T69D/N V60I 
L228R 
P<0,05 
P<0,001 
K173T 
L214F 
P<0,001 
P<0,05 
L74I   V245Q P<0,05 
V75T/I G196R/M/E P<0,01 S48T/Q 
T200A 
P<0,001 
P<0,001 
F77L E122K 
R211T/S 
P<0,05 
P<0,05 
T39E/D 
T200A 
P<0,05 
P<0,01 
V90I/W T39E/D 
S162Y/D/H 
I202V/M 
R211K 
P<0,05 
P<0,01 
P<0,05 
P<0,05 
S48T/Q P<0,01 
Y115F     
F116Y G196R/M/E 
I202V/M 
P<0,05 
P<0,005 
D123S/G 
T200A 
P<0,05 
P<0,05 
V118I V60I 
D123S/G 
P<0,01 
P<0,05 
S48T/Q 
I177E/K/G 
T200A 
L214F 
P<0,05 
P<0,001 
P<0,05 
P<0,001 
Q151M I135T/M 
G196R/M/E 
R211T/S 
I202V/M 
P<0,05 
P<0,001 
P<0,001 
P<0,001 
  
 
 
Among the most relevant associations there is a good level of significance between L228R 
(positive) and K173T (negative) with the T69D/N mutation. A good number of negative 
associations for S48T/Q and T200A are also observed. 
 
 
 NNRTI 
 Positive associations negative associations 
A98G V60I 
I178L/M 
R211K 
L228R 
P<0,001 
P<0,05 
P<0,01 
P<0,001 
S48T/Q P<0,05 
K101H/E/P V60I 
E122K/G/P 
P<0,05 
P<0,05 
S48T/Q P<0,01 
K103H/N T39E/D 
I135T/M 
P<0,01 
P<0,05 
G196R/M/E P<0,05 
V106M   L214F P<0,005 
V106A I202V/M 
R211T/S 
L228R 
P<0,01 
P<0,001 
P<0,05 
S48T/Q 
L214F 
P<0,01 
P<0,001 
V108I V60I 
D123S/G 
I135T/M 
I178L/M 
L228R 
P<0,01 
P<0,05 
P<0,005 
P<0,05 
P<0,001 
S48T/Q 
K173T 
P<0,001 
P<0,001 
Y181C/V I135T/M 
K166R/E 
I178L/M 
R211K 
L228R 
P<0,05 
P<0,05 
P<0,005 
P<0,001 
P<0,001 
S48T/Q P<0,001 
Y188L/H I178L/M P<0,05   
G190A/S E122K/G/P 
Q174K 
P<0,05 
P<0,001 
K166R/E P<0,01 
P225H L228R P<0,01 V245Q P<0,05 
 
 
Many relevant associations emerged from the comparisons between resistance mutations to 
NNRTIs and new polymorphisms. In particular the associations of: T39E/D with K103H/N, 
R211K and L228R with Y181C/V, E122K and Q174K with G190A/S. Moreover, S48T/Q is 
also associated in this case in a negative way with different resistance mutations. 
 The associations highlighted by a previous study on subtype B (154) have been collected in 
this table and combined with the most solid evidence emerging from this work 
 Previous study Experimental study 
Positive association 
with NAM-1 
T39A 
K43E/Q/N 
H208Y 
R211K 
L214F 
K223E/Q 
V60I 
(L228R) 
Positive association 
with NAM-2 
E203K/D 
L214L 
D218E 
L228H 
L228R 
(V60I) 
(I135T/M) 
Positive association 
with M184V 
K101E/Q/P 
E203K/D 
L214L 
D218E 
I135T/M 
L228R 
Positive association for 
other mutation  NRTI 
T39A 
K43E/Q/N 
K101E/Q/P 
E122E/P 
E203K/D 
H208Y 
R211K 
L214L 
D218E 
H221Y 
K223E/Q 
T39A 
V60I 
I135T/M 
G196R/M/E 
I202V/M 
R211T/S 
Negative association 
with NAM1 
 S48Q/T 
Negative association 
with NAM2 
R83K S48Q/T 
K173T 
Negative association 
with M184V 
 V245Q 
S48T/Q 
K166R/E 
L214F 
Negative association 
for other mutation with  
NRTI 
 S48T/Q 
K173T 
I177E/K/G 
T200A 
L214F 
 
The only concordances found in the comparison with the previous study concern the 
association of L228R with the mutations of the NAM-2 pathway and of T39A with the 
mutations for NRTI. 
It is to be considered that a good part of the new mutations considered from the previous 
study have not been analyzed because they were found to be too low, and therefore cannot 
be reconfirmed by our study. Vice versa, many of the high frequency polymorphisms included 
in our study did not appear in the work on subtype B. 
 
NNRTI 
Positive association Negative association 
V60I/V 
E122K/G/P 
I135T/M 
Q174K 
I178L/M 
R211K 
L228R 
S48T/Q 
K166R/E 
L214F 
 
The associations with the NNRTI mutations have not been studied in the previous work on the 
subtype, so there is no direct comparison. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
The study showed that in Malawi there is an increase in NNRTI resistance and that the 
activity of NNRTIs is compromised because of the high level of threshold NNRTI resistance. 
However in developing African countries, the majority of first line ART regimens are NVP/EFV 
based, even if these drugs are responsible for selection of mutations to the entire class of 
NNRTI (K103N, Y181C and G190A). 
It should be considered that in Malawi, like in developing countries , the resistance test in a 
patient that has to start the ART therapy is not provided. This could cause a choice of a sub-
optimal therapy for the patient since the viral sequencing is done only in case of treatment 
failure and the epidemiological surveillance is just starting now. 
The study confirms a review of treatment protocols because the use of NNRTIs could be the 
cause in the increase of resistance, and confirms the need of the planned shift to a first line 
with integrase inhibitors drugs. 
The study suggests also that a sequencing test should be done before starting the therapy in 
order to choose an optimal treatment protocol and avoid the insurgence of problems during 
the patient care program. An affordable sequencing method could support this approach. 
Given such levels of HIVDR prevalence, HIVDR testing and surveillance capacity in Malawi 
should be prioritized as the universal access will be adopted for all HIV people. 
  
Following WHO guidance, NNRTI TDR was classified in Malawi as moderate (5%– 15%) but 
we found a high percentage of 29% for NNRTI resistance mutations in our cohort. 
NRTI and PI TDR was classified as low (<5%) but in our study we found a moderate 
percentage of 11,9% for NRTI. In the case of PI, the percentage detected in our study was 
1,8% corresponding to the WHO low classification. The differences could also depend on the 
sample size since our population was composed by 109 patients while WHO analyzed in 
Malawi only 26 sequences. 
  
TDR WHO Malawi classification DREAM RESULTS 
NRTI low moderate 
NNRTI moderate high 
 
 WHO classification:<5% low, between 5 and 15 % moderate, >20% high. 
 
The sequencing of 425 samples of HIV-infected subjects of subtype C residing in Malawi 
allowed us to determine the frequencies of classical resistance mutations and other non-
characterized mutations, or polymorphisms. We investigated whether some of these 
polymorphisms are associated with the presence of resistance mutations.  
We also performed a comparison with a previous study performed in Novara on subjects 
infected with HIV strains of subtype B, to highlight any differences with the already known 
associations. From the information obtained, the polymorphisms studied have been grouped 
into some groups. 
Many of the polymorphisms considered in our study have never been shown in association 
with resistance mutations in subtype B. One of the most exemplary cases is S48T/Q, which is 
negatively associated with mutations of all the considered resistance classes: NAM-pathways 
(NAM-1 and NAM-2), the M184V and the other mutations for NRTI. S48T/Q would therefore 
play a role of "good mutation", i.e. its presence seems to be protective against various 
resistance mutations. 
In some cases a discordant behavior has been evidenced in the associations between 
subtype C and B. The polymorphisms T39A, K43E/D, R211K and L214F are associated in the 
subtype B to the mutation pathway NAM-1, while in the samples of the subtype C there are no 
association with those mutations. The M184V resistance mutation due to its ability to induce 
complete resistance alone to Lamivudine and Emtricitabine was considered separately from 
other NRTI mutations. None of the associations related to it in subtype B were confirmed, 
while new ones emerged, positive for I135T/M and L228R, and negative for V245Q, S48T/Q, 
K166R/E and L214F. All these considerations underline how subtypes B and C are 
characterized by substantially different mutational profiles. It should be noted that many of the 
polymorphisms taken into consideration by the previous study were not found with sufficient 
frequencies to be included in this work, and vice versa, many of the polymorphisms evaluated 
in the present work had not been previously. However this proves once more the hypothesis 
that mutations and polymorphisms arise differently between the two subtypes. The 
associations regarding resistance mutations for NNRTI with subtype B could not be compared 
because they have not yet been investigated, but equally interesting data emerged.  
Three polymorphisms positively associated to mutations that could determine a reduction in 
susceptibility to Efavirenz (EFV) and Nevirapine (NVP) were found with very high frequency 
(81.2% for T39E/D associated to K103H/N, 55.0% for Q174K  associated to G190A and 
71.3% for R211K strongly  associated  to Y181C) enough to be considered part of the 
consensus sequence of the subtype C.For their association with resistance mutations, it could 
be suspected that they have a role in making the subtype C naturally more likely to develop 
resistance to NNRTIs. An interesting consideration can also be made regarding the 
synonymous V106V mutation. The GTA variant is common in subtype B and "prepares" this 
codon for a possible evolution to V106A, responsible for resistance to Nevirapine. Instead, in 
subtype C we find the GTG triplet, which offers a lower genetic barrier for the V106M 
mutation, responsible for NNRTI multi-resistance. 
Combining the results we obtained through the naive patients cohort and the polymorphisms 
analysis. we can conclude that guidelines for HIV treatment should be globally revised.  
Indeed, studying the cohort of naive patients, we identified an important frequency on some 
drug resistance mutations and we discovered also different polymorphisms pathways 
between subtype B and C: our hypothesis is that different subtypes behave differently in the 
induction of the resistances.  
The fact that polymorphisms and resistance mutations are so different between B and C 
subtypes, indicates that mutational pathways are different and it is possible that while 
treatment with NVP and EFV in the subtype B rarely induces resistances, maybe in subtype C 
instead it could favor them more easily.  
Since all the scientific studies about treatment guidelines for HIV  have always been based 
preferentially on subtype B virus, diffused in western world, similar studies should be 
conducted on other subtypes and guidelines should be modified and target subtype-based 
guidelines should be created. 
 
 
 
 
Future perspectives 
 
Especially for polymorphisms study, were registered some difficulties in collecting samples 
after initiation of the treatment from patients we enrolled for naive analysis, because following 
the therapeutic protocol, we have to wait one year to have back the patient for molecular test. 
For this reason this is still an ongoing activity and it will be object of future researches in our 
laboratory. 
In the same time, we developed an homemade sequencing method that is a very important 
goal in a setting like Malawi, where commercial methods, developed and successfully used in 
Western Countries, are not affordable to be used in routine activity. This effort was an ethic 
commitment for us, in order to allow a country as Malawi to have the possibility to implement 
a tests also for HIV1 drug resistance diagnostic and studies. For this reason a lot of time, 
efforts, and grants (external to the PhD course) were employed and we are proud of this 
result. The next goal is to apply the same in house method to a different type of samples than 
plasma as Dry Blood Spot (DBS). We will increase dramatically the accessibility to the test 
(as it’s happening for the viral load test), especially in Malawi, where the population lives in 
rural areas.  
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